US Patent Applications in Skin Care Actives and Formulations Published in 2011
US PROVISIONAL PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2011
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications published. Salient search
terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening, blemish removal, etc. This
category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavengers, "green" derived molecules and
compounds having unique sensory properties.

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2011



Application No.: US20110002880A1  Published: 06/Jan/2011

Title: Material For Wound Healing and Skin Reconstruction

Applicant/Assignee: 3-D MATRIX, LTD

Application No.: 12/746520   Filing Date: 04/Dec/2008

Abstract:

The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable [beta]-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.

Priority: JP20070314640 Applic. Date: 2007-12-05; WO2008JP72047 Applic. Date: 2008-12-04

Inventor: TAKAMURA KENTARO [JP]; TAKEI JIRO [JP]


Application No.: US20110002969A1  Published: 06/Jan/2011

Title: COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING METALLOPROTEINASE INHIBITORS

Applicant/Assignee: LIPOTEC, S.A

Application No.: 12/920241   Filing Date: 27/Feb/2009

Abstract:

Peptides of general formula (I): R1AA1-AA2-AA3-AA4-R2 stereoisomers thereof, mixtures thereof or the cosmetically or pharmaceutically acceptable salts thereof, a method for obtaining them, cosmetic or pharmaceutical compositions containing them, and their use for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, mucosae and/or scalp resulting from matrix metalloproteinases (MMP) overexpression or an increase in the MMP activity.

Priority: ES20080000597 Applic. Date: 2008-02-29; WO2009EP01419 Applic. Date: 2009-02-27

Inventor: SERRAIMA CRISTINA CARRENO [ES]; NEST WIM VAN DEN [ES]; PUCHE JUAN CEBRIAN [ES]; DOMENECH NURIA ALMINANA [ES]; MONTIEL ANTONIO FERRER [ES]; SANZ NURIA GARCIA [ES]


Application No.: US20110008455A1  Published: 13/Jan/2011

Title: Crosslinked Protein Nanocrystals, Crosslinked Protein Nanoaggregates and Method of Preparation Thereof

Applicant/Assignee: SABANCI UNIVERSITY

Application No.: 12/831232   Filing Date: 06/Jul/2010

Abstract:

This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of protein nanoparticle precursor materials-i.e., crosslinked proteins of the micron or greater size-via mechanical or hydrodynamic shear, mechanical crushing, sonic cavitation and/or hydrodynamic cavitation.

Priority: US20090223691P Applic. Date: 2009-07-07

Inventor: TARALP ALPAY [TR]


Application No.: US20110009310A1  Published: 13/Jan/2011

Title: Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation

Applicant/Assignee: CELECURE AS

Application No.: 12/660886   Filing Date: 05/Mar/2010

Abstract:

Soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in chick and mouse and thereby inhibits human tumor growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble non glycosylated CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumors using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues are presented.

Priority: US2004-487620 Applic. Date: 2004-05-24

Inventor: STROMBLAD STAFFAN [SE]; KOGERMAN PRIIT [EE]; PALL TAAVI [EE]


Application No.: US20110009332A1  Published: 13/Jan/2011

Title: Therapeutic Treatment Of Wounds

Applicant/Assignee: SOUTHWEST RESEARCH INSTITUTE

Application No.: 12/813217   Filing Date: 10/Jun/2010

Abstract:

The present disclosure relates to compositions and methods for treating wounded skin and/or increasing the mechanical strength of wounded skin through the administration of an effective amount of a proteasome inhibitor to such wounded skin.

Priority: US2009-500196 Applic. Date: 2009-07-09

Inventor: ROSSINI JORGE GIANNY [US]


Application No.: US20110020375A1  Published: 27/Jan/2011

Title: STROMAL CELL-DERIVED FACTOR-1 POLYPEPTIDES, POLYNUCLEOTIDES, MODULATORS THEREOF AND METHODS OF USE

Applicant/Assignee: FIVE PRIME THERAPEUTICS, INC

Application No.: 12/752936   Filing Date: 01/Apr/2010

Abstract:

Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.

Priority: US2008-587651 Applic. Date: 2008-06-30; WO2005US14963 Applic. Date: 2005-04-29; US20040567311P Applic. Date: 2004-04-30

Inventor: CHU KETING [US]; WILLIAMS LEWIS T [US]; WONG JUSTIN G P [US]; HESTIR KEVIN [US]; COLLINS AMY L TSUI [US]; LEE ERNESTINE [US]


Application No.: US20110020437A1  Published: 27/Jan/2011

Title: OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF

Applicant/Assignee: APIM THERAPEUTICS AS

Application No.: 12/918797   Filing Date: 20/Feb/2009

Abstract:

The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3'X1''' (SEQ ED NO: 1), wherein X1 and X1''' are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3' are independently selected from the group of uncharged amino acids

and wherein the oligopeptidic compound is further characterised by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence

(ii) the PCNA interacting motif is [K/R]-F-{LIV]-[LIV]-[K/R] (SEQ ID NO. 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g. myeloablation. In certain aspects the compounds of the invention may be used as cytostatic agents in their own right. In other aspects of the invention oligopeptidic compounds comprising such a motif may be used in conjunction with cytostatic agents or with radiotherapy.

Priority: GB20080003352 Applic. Date: 2008-02-22; US20080100584P Applic. Date: 2008-09-26; WO2009GB00489 Applic. Date: 2009-02-20

Inventor: OTTERLEI MARIT [NO]; AAS PER ARNE [NO]; FEYZI EMADOLDIN [NO]


Application No.: US20110021418A1  Published: 27/Jan/2011

Title: ENRICHED HAPTOGLOBIN POLYMERS FOR THE TREATMENT OF DISEASE

Applicant/Assignee: NHS BLOOD AND TRANSPLANT

Application No.: 12/886290   Filing Date: 20/Sep/2010

Abstract:

Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable.

Priority: US2008-113036 Applic. Date: 2008-04-30; US20070924090P Applic. Date: 2007-04-30

Inventor: DALTON JOAN [GB]; PODMORE ADRIAN [GB]


Application No.: US20110027364A1  Published: 03/Feb/2011

Title: BIOACTIVE AND RESORBABLE SOYBEAN-BASED BIOMATERIALS

Applicant/Assignee: UNIVERSITY OF BRIGHTON

Application No.: 12/744848   Filing Date: 26/Nov/2008

Abstract:

A method of producing a soybean-based biomaterial which is suitable for use in a biomedical product, the method comprising: defatting soy flour

either prior to or at the same time as, performing a solvent extraction

to produce a biomaterial comprising variable levels of soy proteins, carbohydrates and isoflavones. The resulting biomaterials have a range of biomedical uses and are particularly desirable because of their isoflavone content. Examples of biomedical products containing the biomaterials include wound dressings

scaffolds for tissue engineering

fillers or implants for use in surgery

temporary barriers for use in dental or surgical procedures or to prevent post-surgical tissue adherence

carriers for the delivery of drugs, bioactive peptides or plasmids

anti-inflammatory agents

coatings for wound dressings or for dental, medical, surgical or veterinary devices or implants

and compositions for soothing skin or gum irritation.

Priority: GB20070023102 Applic. Date: 2007-11-26; WO2008GB51117 Applic. Date: 2008-11-26

Inventor: AMBROSIO LUIGI [IT]; NICOLAIS LUIGI [IT]; SALVAGE JONATHAN PETER [GB]; SANTIN MATTEO [GB]; STANDEN GUY [GB]


Application No.: US20110028398A1  Published: 03/Feb/2011

Title: METHODS FOR TREATING AND LIMITING FIBROTIC DISORDERS AND KELOIDS

Applicant/Assignee: THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSI

Application No.: 12/305885   Filing Date: 10/Jul/2007

Abstract:

The present invention provides methods for treating and/or limiting fibrotic disorders and/or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and/or limit scars selected from the group consisting of keloids and hypertrophic scars of a polypeptide comprising an HSP20-related polypeptide.

Priority: US20060830279P Applic. Date: 2006-07-12; US20060849041P Applic. Date: 2006-10-02; WO2007US73144 Applic. Date: 2007-07-10

Inventor: LOPES LUCIANA BIAGINI [US]; FURNISH ELIZABETH J [US]; FLYNN CHARLES ROBERT [US]; KOMALAVILAS PADMINI [US]; PANITCH ALYSSA [US]; BROPHY COLLEEN M [US]


Application No.: US20110028403A1  Published: 03/Feb/2011

Title: HSP70-Based Treatment for Autoimmune Diseases and Cancer

Applicant/Assignee: ANAPHORE, INC

Application No.: 12/723388   Filing Date: 12/Mar/2010

Abstract:

A non-natural HSP70 activating region that activates dendritic cells. Polypeptides that bind to the HSP70 activating region can be used to treat autoimmune diseases, such as vitiligo, by binding to HSP70 and preventing HSP70 form activating dendritic cells. The HSP70 binders can be constructed in the form of fusions proteins with a trimerizing structural element that may associate to form a trimeric complex. Pharmaceutical compositions and methods for treating vitiligo using the HSP70 binding proteins, fusion proteins and complexes.

Priority: WO2008US76266 Applic. Date: 2008-09-12; US20070960022P Applic. Date: 2007-09-12; US20080051720P Applic. Date: 2008-05-09

Inventor: LE POOLE ISABELLE CAROLINE [US]; NIELAND JOSEPHUS DIRK [DK]; HOLTET THOR LAS [DK]


Application No.: US20110028404A1  Published: 03/Feb/2011

Title: Composition Comprising Vegetable Peptone for Promoting Stem Cell Proliferation

Applicant/Assignee: BIO SPECTRUM ,INC

Application No.: 12/936055   Filing Date: 19/Mar/2009

Abstract:

The present invention relates to a composition for promoting stem cell proliferation which contains a vegetable peptone. More specifically, this invention relates to: a serum-free composition for culturing stem cells which contains a vegetable peptone

a composition for improving skin condition containing the vegetable peptone as an active ingredient

and a composition for improving skin condition containing a culture medium as an active ingredient in which cultured stem cells are removed after being cultured in a serum-free composition medium for stem cell culture containing the vegetable peptone. Since the disclosed serum-free composition for culturing stem cells does not need the use of expensive animal serum, the manufacturing cost can be remarkably lowered. Also the use of anima serum in the medium can basically prevent contamination material caused by the use of animal serum. In addition, the disclosed composition containing the vegetable peptone and the medium in which the stem cells are cultured in the serum-free medium both serve to promote and activated the proliferation of stem cells, and improve various skin conditions.

Priority: KR20080030237 Applic. Date: 2008-04-01; WO2009KR01415 Applic. Date: 2009-03-19

Inventor: PARK DEOK HOON [KR]; LEE JIENNY [KR]; LEE JONG SUNG [KR]


Application No.: US20110033411A1  Published: 10/Feb/2011

Title: Novel Ammonium-Polyurethane- And/Or Polycarbonate Compounds

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS GMBH

Application No.: 12/921798   Filing Date: 05/Mar/2009

Abstract:

The invention relates to novel compounds, in particular ammonium-polyurethane and/or polycarbonate compounds, in particular ammonium-polyurethane-polydiorganosiloxane and/or polycarbonate-polydiorganosiloxane compounds, methods for their production as well as their use.

Priority: DE200810013583 Applic. Date: 2008-03-11; WO2009EP52593 Applic. Date: 2009-03-05

Inventor: WAGNER ROLAND [DE]; SOCKEL KARL-HEINZ [DE]; SIMON WALTER [DE]


Application No.: US20110033507A1  Published: 10/Feb/2011

Title: Polypeptides KXK and Their Use

Applicant/Assignee: SEDERMA

Application No.: 12/224032   Filing Date: 16/Feb/2006

Abstract:

The invention concerns polypeptides of the general formula (I): A-(Xaa)n-Lys-X-Lys-B wherein: i) A is -NH2, NH3+, or NH-D (D is an acyl group being biotin or an alkyl chain (C2-C22)), H) B is H, O- OR1 or NR2R3 and R1, R2 and R3 independently either: H or an alkyl chain (C1-C24), iii) (Xaa)n is an amino acid chain including any amino acid natural or not, excluding arginine and lysine, iv) "n" is between 0-3, and v) X is either a chain of two any amino acids (Xaa1Xaa2), which may be the same or different, excluding arginine, lysine and excluding Xaa1Xaa2=Thr-Thr, Gly-His and Glu-His, or X is a spacer selected among beta-alanyl, 5-amino-valeroyl, 4-amino-cyclohexanoyl, 4-amino-butyroyl, 6-amino-caproyl and derivatives thereof. More particularly, the invention concerns polypeptides of formula (I) wherein "n" is 0 and with the formula: A-Lys-X-Lys-B

A, X and B being defined herein. Compositions containing at least one of said polypeptides and their use.

Priority: WO2006IB01436 Applic. Date: 2006-02-16

Inventor: LINTNER KARL [FR]; PESCHARD OLIVIER [FR]; MONDON PHILIPPE [FR]; MAS CHAMBERLIN CLAIRE [FR]


Application No.: US20110033509A1  Published: 10/Feb/2011

Title: Cosmetic or dermatological article comprising a medium that is soluble in water

Applicant/Assignee: L'OREAL

Application No.: 12/805327   Filing Date: 26/Jul/2010

Abstract:

The present invention relates to a cosmetic or dermatological article comprising: a medium in the form of at least one sheet of a material that is soluble in water at a temperature lower than 20 DEG C.

and at least one cosmetic or dermatological compound carried by the medium.

Priority: FR20050050014 Applic. Date: 2005-01-03; US2005-303961 Applic. Date: 2005-12-19; US20050658165P Applic. Date: 2005-03-04

Inventor: SIMON PASCAL [FR]


Application No.: US20110033521A1  Published: 10/Feb/2011

Title: Molecules and Methods of Using Same for Treating MCP-1/CCR2 Associated Diseases

Applicant/Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES

Application No.: 11/883725   Filing Date: 10/Apr/2006

Abstract:

Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.

Priority: US20050671476P Applic. Date: 2005-04-15; WO2006IL00454 Applic. Date: 2006-04-10

Inventor: KARIN NATHAN [IL]; WILDBAUM GIZI [IL]; ZOHAR YANIV [IL]; IZHAK LIAT [IL]; WEINBERG URI [IL]


Application No.: US20110034393A1  Published: 10/Feb/2011

Title: USE OF A NOVEL NATURAL AGENT IN COSMETIC COMPOSITIONS

Applicant/Assignee: LESAFFRE ET COMPAGNIE

Application No.: 12/679777   Filing Date: 23/Sep/2008

Abstract:

The invention relates to cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods.

Priority: FR20070006701 Applic. Date: 2007-09-25; WO2008FR01319 Applic. Date: 2008-09-23

Inventor: JUESTEN PETER [FR]; BORREILL DOMINIQUE MARIE NOELLE [FR]


Application No.: US20110035817A1  Published: 10/Feb/2011

Title: SIVA 3, ITS PREPARATION AND USE

Applicant/Assignee: YEDA RESEARCH AND DEVELOPMENT CO., LTD

Application No.: 12/866593   Filing Date: 09/Feb/2009

Abstract:

The present invention relates to a splice variant of SIVA, SIVA3, and to its use.

Priority: IL20080189408 Applic. Date: 2008-02-10; WO2009IL00151 Applic. Date: 2009-02-09

Inventor: WALLACH DAVID [IL]; RAMAKRISHNAN PARAMESWARAN [IN]; KOVALENKO ANDREI [IL]


Application No.: US20110038853A1  Published: 17/Feb/2011

Title: Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE

Application No.: 12/988570   Filing Date: 21/Apr/2009

Abstract:

The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent.

Priority: FR20080052692 Applic. Date: 2008-04-22; FR20080052696 Applic. Date: 2008-04-22; WO2009FR50737 Applic. Date: 2009-04-21

Inventor: RAPOSO GRACA [FR]; DELEVOYE CEDRIC [FR]; TENZA DANIELE [FR]; HURBAIN ILSE [FR]


Application No.: US20110038946A1  Published: 17/Feb/2011

Title: RELEASE OF ANTIBIOTIC FROM INJECTABLE, BIODEGRADABLE POLYURETHANE SCAFFOLDS FOR ENHANCED BONE FRACTURE HEALING

Applicant/Assignee:

Application No.: 12/676710   Filing Date: 05/Sep/2008

Abstract:

A biodegradable polyurethane scaffold, comprising at least one polyisocyante, polyisocyanate prepolymer, or both, at least one polyester polyol, at least one catalyst, wherein the density of said scaffold is from about 50 to about 250 kg m-3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore, and wherein the scaffold incorporates at least one biologically active component in powder form.

Priority: US20070970194P Applic. Date: 2007-09-05; WO2008US75481 Applic. Date: 2008-09-05

Inventor: GUELCHER SCOTT A [US]; HAFEMAN ANDREA E [US]


Application No.: US20110044905A1  Published: 24/Feb/2011

Title: OXYTOCIN ANALOGUES

Applicant/Assignee: FERRING B.V

Application No.: 12/933858   Filing Date: 30/Mar/2009

Abstract:

The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia compromised lactation conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.

Priority: EP20080251739 Applic. Date: 2008-05-19; US20080040973P Applic. Date: 2008-03-31; WO2009IB05351 Applic. Date: 2009-03-30

Inventor: ALAGARSAMY SUDAR [US]; GALYEAN ROBERT [US]; WISNIEWSKI KAZIMIERZ [US]; SCHTEINGART CLAUDIO [US]


Application No.: US20110044919A1  Published: 24/Feb/2011

Title: Compositions With Perfluorinated Ingredients

Applicant/Assignee:

Application No.: 12/671709   Filing Date: 11/Aug/2008

Abstract:

The invention is directed to a cosmetic composition comprising at least one perfluorinated component and at least one aromatic component, wherein the aromatic component is present in an amount sufficient to compatibilize the fluorinated component in the cosmetic composition

transfer resistant, long wearing or other types of cosmetic or pharmaceutical compositions containing the components and a method for compatibilizing a fluorinated component in a cosmetic composition using an aromatic component, and cosmetic compositions containing at least one perfluorinated amide.

Priority: US20070955883P Applic. Date: 2007-08-15; WO2008US72751 Applic. Date: 2008-08-11

Inventor: GIACOMONI PAOLO U [US]; CUMMINS PHILLIP [US]; LENTINI PETER J [US]; TAN MANUEL L [US]; CASTRO JOHN R [US]; SYED ISMAIL AHMED [US]; VANDEROVER GARRETT WILLIAM [US]


Application No.: US20110044974A1  Published: 24/Feb/2011

Title: Peptide analogues comprising at least one type of aminoacylaza-$g(b)3and the use thereof, in particular for therapy

Applicant/Assignee:

Application No.: 10/560163   Filing Date: 11/Jun/2004

Abstract:

The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-[beta]3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.

Priority: FR20030006992 Applic. Date: 2003-06-11; WO2004FR01467 Applic. Date: 2004-06-11

Inventor: BAUDY FLOC H MICHELE [FR]; BUSNEL OLIVIER [FR]; MULLER SYLVIANE [FR]


Application No.: US20110045041A1  Published: 24/Feb/2011

Title: COMPOSITIONS AND METHODS FOR THE DELIVERY OF AGENTS

Applicant/Assignee:

Application No.: 12/933337   Filing Date: 26/Mar/2009

Abstract:

The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.

Priority: US20080040016P Applic. Date: 2008-03-27; WO2009US01910 Applic. Date: 2009-03-26

Inventor: GOLUBOVIC-LIAKOPOULOS NEVENKA [US]; SHAH BHAVDEEP [US]; ANDERSEN ERIK [DK]


Application No.: US20110052493A1  Published: 03/Mar/2011

Title: USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1

Applicant/Assignee: CREABILIS THERAPEUTICS S.P.A

Application No.: 12/614805   Filing Date: 09/Nov/2009

Abstract:

The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.

Priority: EP20040425665 Applic. Date: 2004-09-03; US2007-713789 Applic. Date: 2007-03-05; WO2005EP09528 Applic. Date: 2005-09-05

Inventor: FUMERO SILVANO [IT]; BERTARIONE RAVA ROSSA LUISA [IT]; BARONE DOMENICO G [IT]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]; BORRELLY GILLES [FR]; CANEPA BARBARA [IT]; LORENZETTO CHIARA [IT]


Application No.: US20110052514A1  Published: 03/Mar/2011

Title: USE OF NATURAL ACTIVE SUBSTANCES IN COSMETIC OR THERAPEUTIC COMPOSITIONS

Applicant/Assignee: LESAFFRE ET COMPAGNIE

Application No.: 12/867193   Filing Date: 11/Feb/2009

Abstract:

The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment.

Priority: FR20080000754 Applic. Date: 2008-02-12; WO2009IB00237 Applic. Date: 2009-02-11

Inventor: JUESTEN PETER [FR]; BORREILL DOMINIQUE MARIE NOELLE [FR]; MARQUES WILLIAM [FR]


Application No.: US20110052519A1  Published: 03/Mar/2011

Title: PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS

Applicant/Assignee:

Application No.: 12/865311   Filing Date: 30/Jan/2009

Abstract:

The invention relates to peptide derivatives of general formula (I): R1-AA1-AA2-AA3-AA4-R2 (I) their stereoisomers, mixtures thereof, and their cosmetically or pharmaceutically acceptable salts, a method for obtaining them, cosmetic or pharmaceutical compositions containing them and their use for the treatment, care and/or cleansing of those conditions, disorders and/or pathologies of the skin, mucosae, scalp and/or nails resulting from microorganism proliferation or being at risk of microorganism proliferation.

Priority: ES20080000243 Applic. Date: 2008-01-30; US20080039599P Applic. Date: 2008-03-26; WO2009EP51041 Applic. Date: 2009-01-30

Inventor: CARRENO SERRAIMA CRISTINA [ES]; VAN DEN NEST WIM [ES]; SEMPERE ANA [ES]; FERRER MONTIEL ANTONIO [ES]; CEBRIAN PUCHE JUAN [ES]; ALMINANA DOMENECH NURIA [ES]; PANYELLA COSTA DAVID [ES]; GINESTAR GONZALEZ JOSE [FR]


Application No.: US20110053833A1  Published: 03/Mar/2011

Title: SYNTHETIC PEPTIDES AND THEIR USE

Applicant/Assignee:

Application No.: 12/733885   Filing Date: 17/Oct/2008

Abstract:

At least one embodiment of the present invention relates to new peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.

Priority: EP20070118922 Applic. Date: 2007-10-19; WO2008EP64062 Applic. Date: 2008-10-17

Inventor: MATTSBY-BALTZER INGER [SE]; HANSSON LARS [SE]; BALTZER LARS [SE]; DOLPHIN GUNNAR [FR]


Application No.: US20110053860A1  Published: 03/Mar/2011

Title: COX-2 function and wound healing

Applicant/Assignee:

Application No.: 12/553275   Filing Date: 03/Sep/2009

Abstract:

The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing.

Priority: US2001-953067 Applic. Date: 2001-09-11

Inventor: O'CONNOR J PATRICK [US]


Application No.: US20110059173A1  Published: 10/Mar/2011

Title: COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION

Applicant/Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Application No.: 12/871461   Filing Date: 30/Aug/2010

Abstract:

Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

Priority: US2007-721529 Applic. Date: 2007-06-12; WO2005US46442 Applic. Date: 2005-12-20; US20040638366P Applic. Date: 2004-12-21; US20050671796P Applic. Date: 2005-04-15

Inventor: GOURDIE ROBERT [US]; GHATNEKAR GAUTAM [US]; JOURDAN JANE [US]


Application No.: US20110059885A1  Published: 10/Mar/2011

Title: TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY EICOSANOIDS

Applicant/Assignee: NATURAL ENVIRONMENT RESEARCH COUNCIL

Application No.: 12/866024   Filing Date: 05/Feb/2009

Abstract:

The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.

Priority: GB20080002116 Applic. Date: 2008-02-05; WO2009GB00311 Applic. Date: 2009-02-05

Inventor: LEA SUSAN [GB]; NUNN MILES [GB]; ROVERSI PIETRO [GB]


Application No.: US20110059896A1  Published: 10/Mar/2011

Title: USE OF FURIN CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING

Applicant/Assignee: RENOVO LIMITED

Application No.: 12/624248   Filing Date: 23/Nov/2009

Abstract:

The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.

Priority: GB20020017136 Applic. Date: 2002-07-24; US2005-522222 Applic. Date: 2005-01-24; WO2003GB03159 Applic. Date: 2003-07-23

Inventor: FERGUSON MARK WILLIAM JAMES [GB]; BRUNNER GEORG [DE]


Application No.: US20110059897A1  Published: 10/Mar/2011

Title: Methods for treating a skin wound

Applicant/Assignee: SANTEN PHARMACEUTICAL CO., LTD

Application No.: 12/804773   Filing Date: 29/Jul/2010

Abstract:

A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) or substance P or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable additive.

Priority: JP20010368103 Applic. Date: 2001-12-03; US2007-725761 Applic. Date: 2007-03-20; US2004-497628 Applic. Date: 2004-06-03; WO2002JP12632 Applic. Date: 2002-12-03

Inventor: NISHIDA TERUO [JP]; INUI MAKOTO [JP]; NAKAMURA MASATSUGU [JP]


Application No.: US20110070183A1  Published: 24/Mar/2011

Title: CROSSLINKED POLYSILOXANES, A PROCESS FOR THEIR PREPARATION AND USE OF THE CROSSLINKED POLYSILOXANES IN EMULSIFIER SYSTEMS FOR WATER-IN-OIL EMULSIONS

Applicant/Assignee: EVONIK GOLDSCHMIDT GMBH

Application No.: 12/888603   Filing Date: 23/Sep/2010

Abstract:

The invention relates to crosslinked organopolysiloxanes which are linked by a polyether building block via the Si atoms, to emulsifier systems which have these crosslinked organopolysiloxanes, and also to cosmetic, dermatological or pharmaceutical formulations comprising a crosslinked organopolysiloxane or an emulsifier system comprising these.

Priority: US20090245366P Applic. Date: 2009-09-24

Inventor: NEUMANN THOMAS [DE]; GRUNING BURGHARD [DE]; HOWE ANNA [US]; ADKINS DANA [US]; REDDINGER JERRY [US]


Application No.: US20110070237A1  Published: 24/Mar/2011

Title: METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM

Applicant/Assignee: CALCIMEDICA, INC

Application No.: 12/874024   Filing Date: 01/Sep/2010

Abstract:

Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.

Priority: US2009-388791 Applic. Date: 2009-02-19; US2006-547720 Applic. Date: 2006-07-18; WO2004US06542 Applic. Date: 2004-03-03; US20030451958P Applic. Date: 2003-03-04

Inventor: ROOS JACK [US]; STAUDERMAN KENNETH A [US]; VELICELEBI GONUL [US]; DIGREGORIO PAUL J [US]; OHLSEN KARI LYNN [US]


Application No.: US20110073126A1  Published: 31/Mar/2011

Title: Long-Wearing Glossy Cosmetic Composition

Applicant/Assignee:

Application No.: 12/730350   Filing Date: 24/Mar/2010

Abstract:

A transfer-resistant, single phase aqueous cosmetic compositions are provided. The compositions consist essentially of a water-soluble, film-forming acrylates copolymer and a water-soluble plasticizer for the copolymer. The compositions contain no oils, waxes, surfactants or emulsifiers, are water- and oil-resistant upon drying on the skin, and exhibit high gloss and long-wear and transfer-resistant properties. Compositions containing pigment also demonstrate high color intensity. The compositions are useful as eyeliner, mascara, lipgloss, lipliner, and other cosmetic products.

Priority: US2005-127938 Applic. Date: 2005-05-12

Inventor: MU WELLIN [US]; MCKENNA LINDA CAROL [US]; STEPNIEWSI GEORGE J [US]; LUO DEXIN [US]; NAZAR SHANAN [US]; WANG TIAN XIANG [US]


Application No.: US20110081323A1  Published: 07/Apr/2011

Title: Methods and compositions for organ and tissue functionality

Applicant/Assignee: DASK TECHNOLOGIES, LLC

Application No.: 12/924052   Filing Date: 20/Sep/2010

Abstract:

Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.

Priority: US2006-526202 Applic. Date: 2006-09-21; WO2006US35676 Applic. Date: 2006-09-14; US20050719743P Applic. Date: 2005-09-21

Inventor: KLEINSEK DON [US]; SOTO ADRIANA [US]


Application No.: US20110081344A1  Published: 07/Apr/2011

Title: SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS

Applicant/Assignee: ZYMOGENETICS, INC

Application No.: 12/943181   Filing Date: 10/Nov/2010

Abstract:

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Priority: US2009-489236 Applic. Date: 2009-06-22; US2005-274910 Applic. Date: 2005-11-15; US2001-925055 Applic. Date: 2001-08-08; US20000223827P Applic. Date: 2000-08-08; US20000250876P Applic. Date: 2000-12-01

Inventor: KINDSVOGEL WAYNE R [US]; TOPOUZIS STAVROS [US]


Application No.: US20110081401A1  Published: 07/Apr/2011

Title: DERMAL PATCH COMPRISING CHONDRUS CRISPUS EXTRACT

Applicant/Assignee: BIOPHIL ITALIA S.P.A

Application No.: 12/936452   Filing Date: 09/Apr/2009

Abstract:

The present invention relates to masks for dermal treatment or "patches", based on a vegetal matrix, particularly red algae (Chondrus crispus) extract rich in polymeric thickeners. The invention relates also to compositions, in particular cosmetic and dermopharmaceutical formulations, to the process for their industrial preparation and to their use in cosmetic and pharmaceutical applications.

Priority: IT2008MI00636 Applic. Date: 2008-04-10; WO2009EP02633 Applic. Date: 2009-04-09

Inventor: PANZIERI FEDERICO [IT]; SANTUS GIACOMO [IT]


Application No.: US20110086805A1  Published: 14/Apr/2011

Title: IN VITRO METHOD FOR DIAGNOSING SKIN CANCER

Applicant/Assignee: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Application No.: 12/744172   Filing Date: 21/Nov/2008

Abstract:

The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene

to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell

and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer.

Priority: FR20070059193 Applic. Date: 2007-11-21; WO2008EP66028 Applic. Date: 2008-11-21

Inventor: SOUFIR NADEM [FR]


Application No.: US20110091403A1  Published: 21/Apr/2011

Title: OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE

Applicant/Assignee:

Application No.: 12/977317   Filing Date: 23/Dec/2010

Abstract:

Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors

general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa

for general oral care, as well as treatment and prevention of oral and gum diseases

and for wound healing of the skin. Methods may comprise using compositions comprising oligosaccharide aldonic acids and additional cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.

Priority: US2009-643215 Applic. Date: 2009-12-21; US2007-872459 Applic. Date: 2007-10-15; US2004-811998 Applic. Date: 2004-03-30; US2001-987023 Applic. Date: 2001-11-13; US2000-487228 Applic. Date: 2000-01-19; US19990141264P Applic. Date: 1999-06-30

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]


Application No.: US20110091485A1  Published: 21/Apr/2011

Title: MODULATION OF CELL JUNCTIONS

Applicant/Assignee:

Application No.: 12/672290   Filing Date: 06/Aug/2008

Abstract:

The present invention provides methods of modulating cell junctions via the Gp140 membrane protein. Gp140 agonists and antagonists are provided, including activating and non-activating antibodies of Gp140, as well as compositions including the same. Methods of treatment including administration of a Gp140 agonist or antagonist are also provided. Finally, implants having a Gp140 modulator coupled thereto are provided.

Priority: US20070954177P Applic. Date: 2007-08-06; WO2008US09432 Applic. Date: 2008-08-06

Inventor: CARTER WILLIAM G [US]; DUNN CLARENCE [US]; WAYNER ELIZABETH [US]; ZAITSEVSKAIA-CARTER TATIANA [US]


Application No.: US20110092431A1  Published: 21/Apr/2011

Title: SKIN AGING-INHIBITING PEPTIDE

Applicant/Assignee: CALPIS CO., LTD

Application No.: 12/874610   Filing Date: 02/Sep/2010

Abstract:

The present invention provides a peptide and a composition which are suitable for oral ingestion, and which have a skin aging-inhibiting activity, a collagen-production promoting activity, an epidermal turnover promoting activity, and a cutaneous cell-proliferating effect. The present invention also provides a medicament and a functional food which have a skin aging-inhibiting activity, a collagen-production promoting activity, and a cutaneous cell-proliferation promoting activity. The present invention provides a composition including at least one peptide of Asn-Ile-Pro-Pro-Leu, Ile-Pro-Pro-Leu, Ile-Pro-Pro, Pro-Val-Val-Val-Pro-Pro, Val-Pro-Pro-Phe, Val-Pro-Pro, Phe-Pro-Pro-Gln, and Leu-Pro-Pro-Thr.

Priority: JP20080318334 Applic. Date: 2008-12-15; WO2009JP70912 Applic. Date: 2009-12-15

Inventor: OHSAWA KAZUHITO [JP]; UCHIDA NAOTO [JP]; BABA HIDEHIKO [JP]; HATORI MICHIO [JP]; OHKI KOHJI [JP]


Application No.: US20110092437A1  Published: 21/Apr/2011

Title: USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7

Applicant/Assignee:

Application No.: 12/673785   Filing Date: 14/Aug/2008

Abstract:

The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7.

Priority: EP20070114505 Applic. Date: 2007-08-17; WO2008EP60693 Applic. Date: 2008-08-14

Inventor: KRASTEL PHILIPP [CH]; LIECHTY BRIGITTA-MARIA [CH]; SCHMITT ESTHER [CH]; SCHREINER ERWIN PAUL [AT]


Application No.: US20110098229A1  Published: 28/Apr/2011

Title: COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS

Applicant/Assignee:

Application No.: 12/607470   Filing Date: 28/Oct/2009

Abstract:

Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical steroid.

Priority:

Inventor: PAUL HARBHAJAN S [US]


Application No.: US20110104085A1  Published: 05/May/2011

Title: Cosmetic Or Pharmaceutical Compositions Comprising Modified Polysiloxanes With At Least One Carbamate Group

Applicant/Assignee: CLARIANT FINANCE (BVI) LIMITED

Application No.: 12/997460   Filing Date: 06/Jun/2009

Abstract:

Cosmetic or pharmaceutical compositions comprising one or more polysiloxanes functionalized with at least one carbamate group are described. In a preferred embodiment the compositions are emulsions wherein the one or more polysiloxanes may advantageously be used as emulsifier.

Priority: EP20080010779 Applic. Date: 2008-06-13; WO2009EP04090 Applic. Date: 2009-06-06

Inventor: KLUG PETER [DE]; PILZ FREDERIC MAURICE [DE]; KLUTH GUISEPPINA [DE]; STEFFANUT PASCAL [FR]; MEDER MARKUS [US]


Application No.: US20110104091A1  Published: 05/May/2011

Title: Cosmetic Use of Water-Redispersible Powders

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/899873   Filing Date: 07/Oct/2010

Abstract:

Cosmetic compositions comprising water-redispersible polymers are provided, as well as methods for using such compositions in cosmetics that afford powder-to-liquid and moisture-resistant benefits. These cosmetics can provide easier portability, as well as long wear benefits when topically applied to the skin or hair.

Priority: US20090258251P Applic. Date: 2009-11-05

Inventor: MAITRA PRITHWIRAJ [US]; CHAN WENDY [US]


Application No.: US20110104170A1  Published: 05/May/2011

Title: NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

Applicant/Assignee: GENENTECH, INC

Application No.: 12/967886   Filing Date: 14/Dec/2010

Abstract:

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Priority: US2006-537270 Applic. Date: 2006-09-29; US2003-658482 Applic. Date: 2003-09-09; US20020410062P Applic. Date: 2002-09-11

Inventor: BALDWIN DARYL T [US]; BODARY SARAH C [US]; CHEN ANDREW C [US]; CLARK HILARY [US]; JACKMAN JANET K [US]; WOOD WILLIAM I [US]


Application No.: US20110104225A1  Published: 05/May/2011

Title: POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR

Applicant/Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD, THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER

Application No.: 12/673520   Filing Date: 13/Aug/2008

Abstract:

A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide

or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.

Priority: US20070935487P Applic. Date: 2007-08-15; WO2008IL01120 Applic. Date: 2008-08-13

Inventor: ROCHKIND SHIMON [IL]; NEVO ZVI [IL]


Application No.: US20110104247A1  Published: 05/May/2011

Title: COMPOSITION FOR STABILIZING BETA-BLOCKER AND TRANSDERMALLY ABSORBABLE PREPARATION COMPRISING THE SAME

Applicant/Assignee:

Application No.: 12/934361   Filing Date: 25/Mar/2009

Abstract:

The present invention relates to a transdermally absorbable composition which is capable of retaining a [beta]-blocker stably for a long period. More specifically, the present invention relates to a transdermally absorbable composition for stabilizing a [beta]-blocker, which comprises a polymer compound having an amino group, a polyvalent carboxylic acid ester, a fatty acid ester and an acrylic polymer compound.

Priority: JP20080077903 Applic. Date: 2008-03-25; WO2009JP55964 Applic. Date: 2009-03-25

Inventor: ITO TAKESHI [JP]; ISHIGURE MIHO [JP]


Application No.: US20110105382A1  Published: 05/May/2011

Title: CALMODULIN-BINDING PEPTIDES THAT REDUCE CELL PROLIFERATION IN CANCER AND SMOOTH MUSCLE PROLIFERATION DISEASES

Applicant/Assignee:

Application No.: 12/674368   Filing Date: 19/Aug/2008

Abstract:

The invention relates to an isolated peptide comprising all or part of the amino acid sequence: GGAEFSARSR KRKANVTVFL QD (SEQ ID NO: 2), wherein the peptide reduces cell proliferation. The invention also includes variants, such as SEQ ID NO:3-5 and fragments of at least 5 amino acids of SEQ ID NO:2-5 that reduce cell proliferation. The peptides are useful for treating cancer and diseases characterized by smooth muscle proliferation, such as restenosis.

Priority: US20070957361P Applic. Date: 2007-08-22; WO2008CA01474 Applic. Date: 2008-08-19

Inventor: HUSAIN MANSOOR [CA]; CHOI JAEHYUN [CA]


Application No.: US20110110873A1  Published: 12/May/2011

Title: Personal Care Compositions Having Improved Compatibility and Providing Improved Sun Protection

Applicant/Assignee: DOW CORNING CORPORATION

Application No.: 12/993867   Filing Date: 06/Jul/2009

Abstract:

Personal care composition having improved compatibility and providing improved sun protection are obtained by including a liquid silicone resin having greater than 50 mole percent Me3SiO1/2 and PrSiC3/2 units, where Me is methyl and Pr is propyl in the composition. If desired to enable additional compatibility of ingredients comprising the personal care composition, the liquid silicone resin can also contain PhSiO3/2 or Ph2SiO2/2 units, where Ph is phenyl, or a mixture thereof.

Priority: US20080084635P Applic. Date: 2008-07-30; WO2009US49662 Applic. Date: 2009-07-06

Inventor: HORSTMAN JOHN BERNARD [US]; KING DOUGLAS W [US]; PRETZER PAUL W [US]; SCHMIDT RANDALL [US]; WIEBER GARY [US]; LEAYM TINA [US]; PRETZER MARIA R [US]


Application No.: US20110110922A1  Published: 12/May/2011

Title: Wound Healing Peptides and Methods of Use Thereof

Applicant/Assignee: TUFTS UNIVERSITY

Application No.: 12/811124   Filing Date: 08/Jan/2009

Abstract:

Methods and compositions for the treatment of wounds in a mammalian subject are provided. Particularly, novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation are provided.

Priority: US20080010401P Applic. Date: 2008-01-08; WO2009US30463 Applic. Date: 2009-01-08

Inventor: HERMAN IRA M [US]


Application No.: US20110112016A1  Published: 12/May/2011

Title: COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM

Applicant/Assignee: BIOLNCEPT, LLC

Application No.: 12/786290   Filing Date: 24/May/2010

Abstract:

A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.

Priority: US2006-381818 Applic. Date: 2006-05-05; US2004-971760 Applic. Date: 2004-10-22; US2005-110990 Applic. Date: 2005-04-20; US20060765400P Applic. Date: 2006-02-03; US20060765393P Applic. Date: 2006-02-03; US20060765398P Applic. Date: 2006-02-03; US20060746511P Applic. Date: 2006-05-05

Inventor: BARNEA EYTAN R [US]


Application No.: US20110117082A1  Published: 19/May/2011

Title: Soluble Tumor Necrosis Factor Receptor Mutant

Applicant/Assignee: SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD, TAIZHOU FUDAN-ZHANGJIANG PHARMACEUTICAL CO., LTD

Application No.: 12/745724   Filing Date: 12/Jan/2009

Abstract:

A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.

Priority: CN20081038410 Applic. Date: 2008-05-30; WO2009CN00037 Applic. Date: 2009-01-12

Inventor: LIU YANJUN [CN]; YANG TONG [CN]; SHEN YIJUN [CN]; WU JINSONG [CN]; WU FANG [CN]


Application No.: US20110117167A1  Published: 19/May/2011

Title: METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR

Applicant/Assignee: AFFINERGY, INC

Application No.: 12/949104   Filing Date: 18/Nov/2010

Abstract:

Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.

Priority: US20090262353P Applic. Date: 2009-11-18; US20100368849P Applic. Date: 2010-07-29; US20100370723P Applic. Date: 2010-08-04

Inventor: SANFORD ISAAC GILLIAM [US]; JANSEN MICHELLE STEFFEN [US]; HAMILTON PAUL THEODORE [US]; HODGES JONATHAN ALLEN [US]; NAIR SHRIKUMAR AMBUJAKSHAN [US]; CHEN YUCHEN [US]; DARBY MARTYN KERRY [US]; GRON HANNE [US]; SATHYA GANESAN [US]


Application No.: US20110118186A1  Published: 19/May/2011

Title: SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF

Applicant/Assignee: CARA THERAPEUTICS, INC

Application No.: 12/773992   Filing Date: 05/May/2010

Abstract:

The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: wherein Xaa is a D-amino acid and G is selected from the following three groups: The compounds are useful in the prophylaxis and treatment of pain, pruritis and inflammation associated with a variety of diseases and conditions.

Priority: US2008-119311 Applic. Date: 2008-05-12; US2007-938771 Applic. Date: 2007-11-12; US2007-938776 Applic. Date: 2007-11-12; US20060858109P Applic. Date: 2006-11-10; US20070928550P Applic. Date: 2007-05-10; US20060858120P Applic. Date: 2006-11-10; US20060858121P Applic. Date: 2006-11-10; US20060858123P Applic. Date: 2006-11-10; US20070928527P Applic. Date: 2007-05-10; US20070928551P Applic. Date: 2007-05-10; US20070928557P Applic. Date: 2007-05-10

Inventor: SCHTEINGART CLAUDIO D [US]; MENZAGHI FREDERIQUE [US]; JIANG GUANGCHENG [US]; ALEXANDER ROBERTA VEZZA [US]; SUEIRAS-DIAZ JAVIER [US]; SPENCER ROBERT H [US]; CHALMERS DEREK T [US]; LUO ZHIYONG [US]


Application No.: US20110118190A1  Published: 19/May/2011

Title: Postsynaptically Targeted Chemodenervation Agents and Their Methods of Use

Applicant/Assignee:

Application No.: 12/867975   Filing Date: 19/Feb/2009

Abstract:

Improved chemodenervation agents are provided comprising polypeptide [alpha]-neurotoxins having high binding specificity and selectivity for the human muscular [alpha]1 nAChR instead of the human neuronal [alpha]7 nAChR, along with pharmaceutical compositions and methods of use.

Priority: US20080066347P Applic. Date: 2008-02-19; WO2009US34578 Applic. Date: 2009-02-19

Inventor: PETERS LARS ERIK [US]; LORENZ TODD [US]


Application No.: US20110123466A1  Published: 26/May/2011

Title: PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING AN ACTIVE PRINCIPLE ACTIVATOR OF CYTOCHROME C

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A (ISP VINCIENCE)

Application No.: 12/597857   Filing Date: 23/Apr/2008

Abstract:

A cosmetic or pharmaceutical, and in particular a dermatological one, including, in physiologically adapted medium, an active principle capable of activating cytochrome C. This active principle may be composed of polypeptides or of peptides, used alone or in association with at least one other active principle. This active principle may also be included in a cosmetic composition intended to stimulate the functions of the mitochondria and to increase the cellular energy level. The active principle be also be used in a cosmetic-treatment procedure intended to protect the skin and the appendages from external aggressions and to combat cutaneous aging.

Priority: FR20070003057 Applic. Date: 2007-04-27; WO2008FR00578 Applic. Date: 2008-04-23

Inventor: DAL FARRA CLAUDE [FR]


Application No.: US20110124567A1  Published: 26/May/2011

Title: THERAPEUTIC COMPOUNDS AND METHODS

Applicant/Assignee:

Application No.: 12/897146   Filing Date: 04/Oct/2010

Abstract:

Therapeutic agents and methods useful to modulate the activity of V3.

Priority: US2002-270253 Applic. Date: 2002-10-11; WO2001US11940 Applic. Date: 2001-04-12; US20000196805P Applic. Date: 2000-04-13

Inventor: WIGHT THOMAS N [US]; MERRILEES MERVYN J [NZ]


Application No.: US20110124569A1  Published: 26/May/2011

Title: MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: 12/677093   Filing Date: 09/Sep/2008

Abstract:

The instant invention describes macrocyclic depsipeptide lyngbyastatins, and methods of treating disorders such as COPD, emphysema, rheumatoid arthritis, and aging related disorders.

Priority: US20070970990P Applic. Date: 2007-09-09; US20080135941P Applic. Date: 2008-07-25; WO2008US10560 Applic. Date: 2008-09-09

Inventor: LUESCH HENDRIK [US]; TAORI KANCHAN [US]; PAUL VALERIE J [US]; MATTHEW SUSAN [US]


Application No.: US20110124572A1  Published: 26/May/2011

Title: SYNDECAN-4 IS A REGULATOR OF RAC1-GTP

Applicant/Assignee:

Application No.: 13/055638   Filing Date: 24/Jul/2009

Abstract:

The present invention provides a method for modulating the activity of Rac1, comprising modifying the phosphorylation state of Ser179 in syndecan-4 through influencing the interaction between syndecan-4 and the guanin nucleotide exchange factor of Rac1 (RacGEF) named Tiam1 in a GTP-dependent manner. In particular, methods are provided for enhancing the epithelial phenotype of a cell and for initiating the polarization of a cell by increasing the de-phosphorylation of said Ser179 of syndecan-4, and for enhancing the migratory phenotype of a cell and for initiating the neuronal differentiation of a cell by increasing the phosphorylation of said Ser179 of syndecan-4. Polypeptides for use in modulating the activity of the small GTPase Rac are also provided, as well as a method for identifying an agent capable of indirectly modulating the activity of the small GTPase Rac 1.

Priority: HU20080000464 Applic. Date: 2008-07-24; WO2009IB53218 Applic. Date: 2009-07-24

Inventor: SZILAK LASZLO [HU]; KELLER-PINTER ANIKO [HU]; LETOHA TAMAS [HU]; TIMAR JOZSEF [HU]


Application No.: US20110124573A1  Published: 26/May/2011

Title: Osmoprotective Complexes for Prevention of Intra-cellular Dehydration in Mammals

Applicant/Assignee: ISLAND KINETICS INC

Application No.: 13/015805   Filing Date: 28/Jan/2011

Abstract:

This invention relates to certain Aloesin derivatives with natural amino acids, peptides, and amino sugars (formula I). The compounds of the present invention possess osmoprotective properties, which are suitable for topical or oral application to treat dermatological disorders including challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn

mitochondrial dysfunction, age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, scalp dryness, skin depigmentation, intracellular dehydration, and combinations thereof:

Priority: US2006-309437 Applic. Date: 2006-08-04

Inventor: GUPTA SHYAM K [US]; WALKER LINDA [US]


Application No.: US20110130338A1  Published: 02/Jun/2011

Title: USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES

Applicant/Assignee: DERMADIS SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Application No.: 12/863651   Filing Date: 21/Jan/2009

Abstract:

This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.

Priority: US20080022386P Applic. Date: 2008-01-21; US20080006576P Applic. Date: 2008-01-22; WO2009IB00089 Applic. Date: 2009-01-21

Inventor: DEPERTHES DAVID [CH]; KUNDIG CHRISTOPH [CH]; HOVNANIAN ALAIN [FR]; DERAISON CELINE [FR]


Application No.: US20110130705A1  Published: 02/Jun/2011

Title: THERAPY FOR VITILIGO

Applicant/Assignee: CLINUVEL PHARMACEUTICALS LIMITED

Application No.: 12/934024   Filing Date: 27/Mar/2009

Abstract:

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

Priority: AU20080901461 Applic. Date: 2008-03-27; WO2009EP02265 Applic. Date: 2009-03-27

Inventor: WOLGEN PHILIPPE [AU]


Application No.: US20110135652A1  Published: 09/Jun/2011

Title: Novel Use of Idbf

Applicant/Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY

Application No.: 13/057473   Filing Date: 03/Aug/2009

Abstract:

There are provided Idbf (inhibitor of Dvl and Bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/[beta]-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/[beta]-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/[beta]-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/[beta]-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/[beta]-catenin signaling pathway.

Priority: KR20080076128 Applic. Date: 2008-08-04; WO2009KR04338 Applic. Date: 2009-08-03

Inventor: CHOI KANG-YELL [KR]; KIM HYUN-YI [KR]; YOON JU-YONG [KR]


Application No.: US20110135742A1  Published: 09/Jun/2011

Title: CONTROLLED RELEASE ENCAPSULATED ANTI-BACTERIAL AND ANTI-INFLAMMATORY NANOPARTICLES

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 12/303166   Filing Date: 19/Jun/2007

Abstract:

This invention pertains to the formulation of nanoparticles that have intrinsic antimicrobial and anti-inflammatory activity. The nanoparticles can be impregnated with one or more therapeutic agents and thereby enhance the antimicrobial and/or anti-inflammatory activity of such agents, and also other properties that the therapeutic agents provide.

Priority: US20060815286P Applic. Date: 2006-06-20; WO2007US71580 Applic. Date: 2007-06-19

Inventor: KIM JENNY [US]; FRIEDMAN ADAM [US]; MODLIN ROBERT [US]


Application No.: US20110142819A1  Published: 16/Jun/2011

Title: METHOD OF IMPROVING WOULD HEALING

Applicant/Assignee: OMNIO HEALER AB

Application No.: 12/863161   Filing Date: 21/Jan/2009

Abstract:

This invention relates to novel methods of promoting the healing or closure of perforated tympanic membranes or wounds, as well as methods for minimizing scar formation and removing necrotic tissue. In particular the invention relates to the use of components of the plasminogen activating system, especially mini-plasminogen, mini-plasmin, micro-plasminogen, micro-plasmin, delta-plasminogen, and delta-plasmintopromote wound healing processes.

Priority: US20080022533P Applic. Date: 2008-01-22; WO2009SE50057 Applic. Date: 2009-01-21

Inventor: NY TOR [SE]; LI JINAN [SE]; HELLSTROM STEN [SE]; ERIKSSON PER-OLOF [SE]


Application No.: US20110142833A1  Published: 16/Jun/2011

Title: METHODS FOR TREATING AND PREVENTING FIBROSIS

Applicant/Assignee:

Application No.: 13/030840   Filing Date: 18/Feb/2011

Abstract:

The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

Priority: US2006-402885 Applic. Date: 2006-04-13; US20050671374P Applic. Date: 2005-04-14

Inventor: YOUNG DEBORAH A [US]; WYNN THOMAS A [US]; COLLINS MARY [US]; GRUSBY MICHAEL J [US]


Application No.: US20110143995A1  Published: 16/Jun/2011

Title: NOVEL ANTI-ALLERGIC AGENTS

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: 12/942900   Filing Date: 09/Nov/2010

Abstract:

The present invention discloses novel complex molecules useful as anti-allergic agents. These complex molecules include in particular, peptidic or peptidomimetic molecules, having a first segment which is competent for cell penetration and a second segment which is able to reduce or abolish mast cell degranulation, and in particular to reduce or abolish allergy mediators such as histamine secretion from mast cells. Specific examples of peptides with the desired activity are disclosed.

Priority: IL19990130526 Applic. Date: 1999-06-17; US2002-009809 Applic. Date: 2002-04-26; WO2000IL00346 Applic. Date: 2000-06-14

Inventor: EISENBERG RONIT [IL]; RAZ TAMAR [IL]


Application No.: US20110150786A1  Published: 23/Jun/2011

Title: COMPOSITION CONTAINING A VOLATILE LINEAR ALKANE, AN AMINATED SILICONE AND A VEGETABLE OIL

Applicant/Assignee: L'OREAL

Application No.: 12/970988   Filing Date: 17/Dec/2010

Abstract:

Composition containing, in a cosmetically acceptable medium, one or more volatile linear alkanes, at least 0.5 wt. % of one or more aminated silicones relative to the total weight of the cosmetic composition, and one or more vegetable oils different from the volatile linear alkanes. Use thereof for the treatment of keratinous materials, preferably of keratin fibres such as the hair.

Priority: FR20090059526 Applic. Date: 2009-12-23; US20100296497P Applic. Date: 2010-01-20

Inventor: DESENNE PATRICIA [FR]; CHESNEAU LAURENT [FR]


Application No.: US20110150799A1  Published: 23/Jun/2011

Title: Block Copolymer and Ester-Terminated Polyesteramide Composition and Uses Thereof

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/645919   Filing Date: 23/Dec/2009

Abstract:

Compositions and methods for the preparation of a composition comprising a block copolymer and ester-terminated polyester amide solubilized in a compatible solvent are disclosed. The disclosed compositions are long-lasting, transfer resistant, flexible, and water-proof capable of complexing the active ingredient to provide such benefits. The disclosed compositions are useful for formulating cosmetics, personal care products, cosmeceuticals, and the like.

Priority:

Inventor: SHAH ARVIND N [US]; ROBINSON FREDA E [US]; CRUZ KATHY [US]; BINDER DAVID ALAN [US]; MAITRA PRITHWIRAJ [US]


Application No.: US20110150818A1  Published: 23/Jun/2011

Title: Silicone-Organic Hybrid Emulsions In Personal Care Applications

Applicant/Assignee:

Application No.: 13/060479   Filing Date: 28/Aug/2009

Abstract:

Personal care compositions containing silicone polymer and organic polymer containing alloy and/or hybrid emulsions are disclosed. The silicone organic hybrid emulsions are particularly useful in hair care formulations to simultaneously provide conditioning and styling benefits. The silicone organic hybrid emulsions are also useful in color cosmetic formulations to provide shine and wash-off resistance benefits.

Priority: US20080092798P Applic. Date: 2008-08-29; WO2009US55268 Applic. Date: 2009-08-28

Inventor: CANFIELD LYLENETTE [US]; JOHNSON BETHANY K [US]; MEYERS DEBORAH LYNN [US]; SCAVUZZO CONCETTINA [BE]; SHOPE MARILYN PATRICK [US]; SWANTON BRIAN JEFFERY [US]; VINCENT ANNE MARIE [BE]


Application No.: US20110150830A1  Published: 23/Jun/2011

Title: COVALENT CONJUGATES BETWEEN ENDOPEROXIDES AND TRANSFERRIN AND LACTOFERRIN RECEPTOR-BINDING AGENTS

Applicant/Assignee: WASHINGTON, UNIVERSITY OF

Application No.: 13/027112   Filing Date: 14/Feb/2011

Abstract:

The invention relates to covalent conjugates between endoperoxides and small peptides and organic compounds that bind to molecular cavities on the transferrin or lactoferrin receptor, and the use of compositions comprising these conjugates to treat cancer, hyperproliferative disorders, inflammatory diseases, and infections.

Priority: US2007-692866 Applic. Date: 2007-03-28; US20060743851P Applic. Date: 2006-03-28

Inventor: SASAKI TOMIKAZU [US]; LAI HENRY CHIU-YUEN [US]; SINGH NARENDRA PAL [US]; OH STEVE J [US]


Application No.: US20110150860A1  Published: 23/Jun/2011

Title: NOVEL 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 AND 49933 MOLECULES AND USES THEREFOR

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 12/755449   Filing Date: 07/Apr/2010

Abstract:

The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Priority: US2008-150094 Applic. Date: 2008-04-24; US2006-445606 Applic. Date: 2006-06-02; US2003-377072 Applic. Date: 2003-02-27; US2001-895860 Applic. Date: 2001-06-29; US2000-723806 Applic. Date: 2000-11-28; US2001-843297 Applic. Date: 2001-04-25; US2001-861801 Applic. Date: 2001-05-21; US2001-816494 Applic. Date: 2001-03-23; US2001-888911 Applic. Date: 2001-06-25; US2001-908664 Applic. Date: 2001-07-17; US2001-935291 Applic. Date: 2001-08-21; US20000215370P Applic. Date: 2000-06-29; US20000187455P Applic. Date: 2000-03-07; US20000199801P Applic. Date: 2000-04-26; US20000205508P Applic. Date: 2000-05-19; US20000213688P Applic. Date: 2000-06-23; US20000218675P Applic. Date: 2000-07-17; US20000250932P Applic. Date: 2000-11-30; US20000226504P Applic. Date: 2000-08-21

Inventor: CURTIS RORY A J [US]; LOGAN THOMAS JOSEPH [US]; GLUCKSMANN MARIA ALEXANDRA [US]; MEYERS RACHEL E [US]; WILLIAMSON MARK J [US]; RUDOLPH-OWEN LAURA A [US]; CHUN MIYOUNG [US]; TSAI FONG-YING [US]


Application No.: US20110150872A1  Published: 23/Jun/2011

Title: SOLUBLE HETERODIMERIC CYTOKINE RECEPTOR

Applicant/Assignee: ZYMOGENETICS, INC

Application No.: 12/695069   Filing Date: 27/Jan/2010

Abstract:

A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

Priority: US2007-690915 Applic. Date: 2007-03-26; US2003-471151 Applic. Date: 2003-09-08; WO2002US07214 Applic. Date: 2002-03-07; US20010274560P Applic. Date: 2001-03-09; US20010299865P Applic. Date: 2001-06-21

Inventor: CHANDRASEKHER YASMIN A [US]; NOVAK JULIA E [US]; FOSTER DONALD C [US]; XU WENFENG [US]; JASPERS STEPHEN R [US]


Application No.: US20110150890A1  Published: 23/Jun/2011

Title: USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS

Applicant/Assignee:

Application No.: 13/039075   Filing Date: 02/Mar/2011

Abstract:

The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (CGRP) antagonistic effect. Methods are also disclosed for identifying compounds with CGRP antagonist activity which thereby are suitable candidate compounds for treating psoriasis.

Priority: IS20020006496 Applic. Date: 2002-08-12; US2005-524104 Applic. Date: 2005-02-10; WO2003IS00023 Applic. Date: 2003-08-12

Inventor: SVEINSSON BIRKIR [IS]


Application No.: US20110152083A1  Published: 23/Jun/2011

Title: NETWORK COPOLYMER CROSSLINKED COMPOSITIONS AND PRODUCTS COMPRISING THE SAME

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS INC

Application No.: 12/975885   Filing Date: 22/Dec/2010

Abstract:

The present invention provides for a household, agricultural, coating or personal care product composition containing the crosslinked reaction product of a network composition the reaction product of: (i) at least one anionic polymerizable ethylenically unsaturated monomer (I) selected from the group consisting of [CH2-C(R3)C(O)OXa(C2H4O)b(C3H6O)c(C4H8O)d]pP(O)(OY)q(OZ)r where R3-H or alkyl of 1 to about 6 carbon atoms

X=alkyl, aryl, or alkaryl diradical connecting group of 0 to about 9 carbon atoms

a is 0 to about 100

b is 0 to about 100

c is 0 to about 100

d is 0 to about 100

q is 0 to about 2

r is 0 to about 2

p is 1 to about 3 subject to the limitation that p+q+r=3

and Y and Z is H, or metal ion

and CH2-C(R3)C(O)OXa'(C2H4O)b'(C3H6O)c'(C4H8O)d'-SO3-Y) where R3-H or alkyl of from 1 to about 6 carbon atoms

X=alkyl, aryl, or alkaryl diradical connecting group of 0 to about 9 carbon atoms

a' is 0 to about 100

b' is 0 to about 100

c' is 0 to about 100

d' is 0 to about 100

Y is H, or metal ion

and (ii) one or more additional monomers (II) selected from the group consisting of acrylic acid/acrylate, methacrylic acid/methacrylate, acrylamides, vinyl acetate and styrene, which are copolymerizable with (I)

and (iii) a cross-linking agent (III), capable of copolymerizing with (I) and (II).

Priority: US20090289782P Applic. Date: 2009-12-23

Inventor: LU NING [US]; GONZALEZ SIGFREDO [US]; SILVESTRE EMIE M [US]; WANG GENG [US]


Application No.: US20110152197A1  Published: 23/Jun/2011

Title: ANALGESIC EFFECTS OF PEPTIDE TOXIN APETX2

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS-, UNIVERSITE NICE SOPHIA ANTIPOLIS

Application No.: 12/995954   Filing Date: 04/Jun/2009

Abstract:

The invention relates to the use of the peptide toxin APETx2 that blocks the ASIC3 cationic channels and that is derived from the Anthopleura elegantissima sea anemone, and to the use of the analogs and derivatives thereof as a drug, particularly as an analgesic pain associated with the activation of ASIC3 (Acid Sensing Ion Channel 3) channels, in particular pain occurring upon an inflammation and potentially upon any painful situation associated with tissue acidosis (ischemiae, fractures, hematoma, oedema, phlyctena, local infections, tissue lesions, ocular wounds, tumours, etc.)

Priority: FR20080003158 Applic. Date: 2008-06-06; WO2009FR00657 Applic. Date: 2009-06-04

Inventor: DEVAL EMMANUEL [FR]; DIOCHOT SYLVIE [FR]; LAZDUNSKI MICHEL [FR]; LINGUEGLIA ERIC [FR]; NOEL JACQUES [FR]


Application No.: US20110152202A1  Published: 23/Jun/2011

Title: DEVELOPMENT OF C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS

Applicant/Assignee:

Application No.: 12/995828   Filing Date: 02/Jun/2009

Abstract:

The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

Priority: US20080130749P Applic. Date: 2008-06-03; WO2009US03338 Applic. Date: 2009-06-02

Inventor: DU CLOS TERRY W [MX]; MOLD CAROLYN [MX]


Application No.: US20110155165A1  Published: 30/Jun/2011

Title: CLEANSING COMPOSITION

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: 13/045619   Filing Date: 11/Mar/2011

Abstract:

The present invention provides a cleansing composition for the skin or hair, which contains, together with (A) a sulfate type anionic surfactant and (B) an N-acylalanine or a salt thereof, at least one kind of compound selected from (C) an amphoteric surfactant, (D) a cationic polymer, (E) a silicone compound and (F) an oily material, wherein the mixing ratio of (A) and (B) of (A)/(B)=99/1-70/30 (wt %) and the concentration of ingredient (A) or (C) is the highest of all the surfactant components in the composition.

Priority: JP20030129539 Applic. Date: 2003-05-07; US2010-756684 Applic. Date: 2010-04-08; US2005-267504 Applic. Date: 2005-11-07; WO2004JP06116 Applic. Date: 2004-04-28

Inventor: YAMATO NAOYA [JP]; SAITO MASATOSHI [JP]; OSHIMURA EIKO [JP]


Application No.: US20110158924A1  Published: 30/Jun/2011

Title: PHOTO-PROTECTIVE DERMATOLOGICAL FORMULATIONS

Applicant/Assignee: DERMAPLUS, INC

Application No.: 13/046419   Filing Date: 11/Mar/2011

Abstract:

A dermatological formulation is disclosed comprising one or more amino acid-based antioxidants in an amount effective to reduce photodamage to skin exposed to UV radiation, and a dermatologically acceptable carrier, wherein the amino acid-based antioxidant includes an amino acid selected from the group consisting of proline, cysteine, tryptophan, threonine, histidine, serine, methionine, lysine and phenylalanine.

Priority: US2008-180395 Applic. Date: 2008-07-25; US20070951881P Applic. Date: 2007-07-25

Inventor: DICKMAN MARTIN B [US]; ENSLEY BURT D [US]


Application No.: US20110160120A1  Published: 30/Jun/2011

Title: Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders

Applicant/Assignee: SYNERGY PHARMACEUTICALS INC

Application No.: 13/010267   Filing Date: 20/Jan/2011

Abstract:

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

Priority: US2008-133344 Applic. Date: 2008-06-04; US20070933194P Applic. Date: 2007-06-04

Inventor: SHAILUBHAI KUNWAR [US]; JACOB GARY S [US]


Application No.: US20110166076A1  Published: 07/Jul/2011

Title: Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases

Applicant/Assignee: BAC IP B.V

Application No.: 13/063363   Filing Date: 10/Sep/2009

Abstract:

The present invention relates to superantigen-specificantigen-binding proteins comprising an immunoglobulin-derived variable domain that comprises a complete antigen binding site for an epitope on the superantigen in a single polypeptide chain. The antigen-binding proteins of the invention may be used in the treatment skin diseases. The antigen-binding proteins of the invention may be used in compositions for topical administration.

Priority: EP20080164044 Applic. Date: 2008-09-10; US20080095770P Applic. Date: 2008-09-10; WO2009NL50545 Applic. Date: 2009-09-10

Inventor: ADAMS HENDRIK [NL]; MAASSEN BRAM THEODORUS HENDRIKUS [NL]


Application No.: US20110171156A1  Published: 14/Jul/2011

Title: Topical Scar Treatment Composition

Applicant/Assignee: C & H SCIENTIFIC LLC

Application No.: 12/987115   Filing Date: 08/Jan/2011

Abstract:

An anhydrous topical scar treatment product having a water activity of less than 0.50, the product being comprised of (i) a silicone elastomer, (ii) a non-volatile, anhydrous carrier vehicle, (iii) L-ascorbic acid in the form of fine powder, at a concentration of concentration of from 7.5% to 15% by weight, based on the total weight of the anhydrous topical scar treatment product, and (iv) an oil-soluble Vitamin C derivative at a concentration of from 5% to 10% by weight, based on the total weight of the anhydrous topical scar treatment product.

Priority: US20100293456P Applic. Date: 2010-01-08

Inventor: CHRYSOPOULO MINAS [US]; HOFFMAN ROLAND [US]; GOLDSBERRY SUSAN [US]


Application No.: US20110171320A1  Published: 14/Jul/2011

Title: Methods to extend vision to infrared wavelengths

Applicant/Assignee:

Application No.: 10/749095   Filing Date: 17/Dec/2003

Abstract:

In a method for visualizing an object under conditions of low ambient light, the object to be visualized is exposed to incident electromagnetic radiation having a wavelength greater than what can normally be seen by the naked eye. Light reflected from the object is then perceived with an enhanced eye. The enhanced eye contains an up-conversion material optically coupled to the photoreceptors. Up-conversion materials absorb in the infrared and luminesce in the visible. Particles containing such materials are delivered to the eye where they are optically coupled to the retina or photoreceptor cells and nearby tissues. There they provide in-situ up-conversion of infrared frequencies (from about 700 to about 11,000 nm) to the otherwise unaided eye.

Priority: US20030438043P Applic. Date: 2003-01-03

Inventor: DANTUS MARCOS [US]


Application No.: US20110172153A1  Published: 14/Jul/2011

Title: SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION, CHUGAI PHARMACEUTICAL CO., LTD

Application No.: 12/671429   Filing Date: 01/Aug/2008

Abstract:

The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.

Priority: US20070963117P Applic. Date: 2007-08-01; US20070963082P Applic. Date: 2007-08-02; US20070963867P Applic. Date: 2007-08-06; WO2008US09288 Applic. Date: 2008-08-01

Inventor: GARDELLA THOMAS J [US]; POTTS JR JOHN T [US]; SHIMIZU MASARU [JP]; ICHIKAWA FUMIHIKO [JP]; JUPPNER HARALD [US]; OKAZAKI MAKOTO [JP]


Application No.: US20110172160A1  Published: 14/Jul/2011

Title: HEAT-STABLE, AQUEOUS LACTOFERRIN COMPOSITION AND ITS PREPARATION AND USE

Applicant/Assignee: CAMPINA NEDERLAND HOLDING B.V

Application No.: 12/999292   Filing Date: 15/Jun/2009

Abstract:

The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin.

Priority: EP20080158354 Applic. Date: 2008-06-16; WO2009NL50342 Applic. Date: 2009-06-15

Inventor: CAO LINQIU [NL]; MAAS HANS [NL]


Application No.: US20110177998A1  Published: 21/Jul/2011

Title: BIOACTIVE PEPTIDES AND METHODS OF USING SAME

Applicant/Assignee:

Application No.: 12/668712   Filing Date: 11/Jul/2008

Abstract:

Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.

Priority: US20070959370P Applic. Date: 2007-07-12; WO2008IB02447 Applic. Date: 2008-07-11

Inventor: SHEMESH RONEN [IL]; LEVINE ZURIT [IL]; TOPORIK AMIR [IL]; HERMESH CHEN [US]; KLIGER YOSSEF [US]; GOFER EYAL [IL]; WOOL ASSAF [IL]; DAHARY DVIR [IL]; COHEN YOSSI [GB]


Application No.: US20110178010A1  Published: 21/Jul/2011

Title: USE OF PEPTIDES FOR PROMOTING WOUND HEALING

Applicant/Assignee:

Application No.: 12/811928   Filing Date: 07/Jan/2009

Abstract:

The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.

Priority: EP20080075012 Applic. Date: 2008-01-07; NL20082002152 Applic. Date: 2008-10-30; WO2009EP00241 Applic. Date: 2009-01-07

Inventor: BOLSCHER JOHANNES GERHARDUS MARIA [NL]; VAN NIEUW AMERONGEN ARIE [NL]; VEERMAN ENGELMUNDUS CORNELIS IGNATIUS [NL]; OUDHOFF MENNO JOHANNES [NL]; VAN T HOF WILLEM [NL]; NAZMI KAMRAN [NL]; VAN DEN KEIJBUS PETRONELLA ADRIANA MARIA [NL]


Application No.: US20110189131A1  Published: 04/Aug/2011

Title: ACTIVE VARIANTS OF THE IL-18 BINDING PROTEIN AND MEDICAL USES THEREOF

Applicant/Assignee: MERCK SERONO SA

Application No.: 13/074538   Filing Date: 29/Mar/2011

Abstract:

The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof.

Priority: EP20030101326 Applic. Date: 2003-05-13; US2004-556417 Applic. Date: 2004-05-11; WO2004EP05073 Applic. Date: 2004-05-11

Inventor: ALTAROCCA VALTER [IT]; PEZZOTTI ANNA R [IT]


Application No.: US20110190202A1  Published: 04/Aug/2011

Title: Prevention of Cellular Senescence in Mammals by Natural Peptide Complexes

Applicant/Assignee: ISLAND KINETICS INC

Application No.: 13/084709   Filing Date: 12/Apr/2011

Abstract:

Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest. A treatment based on compositions of compound (I) for cellular senescence to control cellular degradation offers such a solution to multiple skin ailments including skin degradation from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn

mitochondrial dysfunction, age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, scalp dryness, skin depigmentation, intracellular dehydration, and combinations thereof

Priority: US2006-309437 Applic. Date: 2006-08-04; US201113015805 Applic. Date: 2011-01-28

Inventor: GUPTA SHYAM K [US]; WALKER LINDA [US]


Application No.: US20110190210A1  Published: 04/Aug/2011

Title: PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF

Applicant/Assignee: CHILDREN'S MEDICAL CENTER CORPORATION

Application No.: 13/015376   Filing Date: 27/Jan/2011

Abstract:

Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.

Priority: WO2009US51971 Applic. Date: 2009-07-28; US20080084052P Applic. Date: 2008-07-28

Inventor: ADINI AVNER [US]; D AMATO ROBERT [US]


Application No.: US20110195039A1  Published: 11/Aug/2011

Title: HAIR BUILDING SOLID AGENT

Applicant/Assignee: PANGAEA LABORATORIES LTD

Application No.: 13/026062   Filing Date: 11/Feb/2011

Abstract:

A method of treating hair comprising applying a hair building solid agent for use on or with one or more of hair, skin and hair building solids for altering and/or maintaining the electrostatic charge of the hair and/or skin such that it has a substantially negative polarity. The method further comprises applying hair building solids to hair before and/or during and/or after applying the hair building solid agent. The hair building solid agent is applied as a spray on to the hair and/or skin and/or hair building solid.

Priority: GB20100002254 Applic. Date: 2010-02-11

Inventor: ISAACS ELLIOT [GB]


Application No.: US20110195102A1  Published: 11/Aug/2011

Title: PEPTIDES USEFUL IN THE TREATMENT AND/OR CARE OF SKIN, MUCOUS MEMBRANES, SCALP AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: LIPOTEC, S.A

Application No.: 13/122435   Filing Date: 02/Oct/2009

Abstract:

Peptides with general formula (I): R1-AA1-AA2-AA3-AA4-R2 its stereoisomers, mixtures thereof, and its cosmetically or pharmaceutically acceptable saits, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment and/or care of conditions, disorders and/or pathologies of the skin, mucous membranes, scalp and/or hair.

Priority: ES20080002818 Applic. Date: 2008-10-03; US20080102576P Applic. Date: 2008-10-03; WO2009EP07075 Applic. Date: 2009-10-02

Inventor: VAN DEN NESTT WIM [ES]; ALMINANA DOMENECH NURIA [ES]; PUCHE JUAN CEBRIAN [ES]; SERRAIMA CRISTINA CARRENO [ES]


Application No.: US20110195900A1  Published: 11/Aug/2011

Title: PEPTIDIC PTH RECEPTOR AGONISTS

Applicant/Assignee: FERRING B.V

Application No.: 13/059622   Filing Date: 19/Aug/2009

Abstract:

Novel peptidic pth receptor agonists and methods of using the same are provided.

Priority: US20080090062P Applic. Date: 2008-08-19; WO2009US54342 Applic. Date: 2009-08-19

Inventor: SCHTEINGART CLAUDIO D [US]; SUEIRAS-DIAZ JAVIER [US]


Application No.: US20110200555A1  Published: 18/Aug/2011

Title: CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN

Applicant/Assignee: FRESENIUS KABI DEUTSCHLAND GMBH

Application No.: 13/018648   Filing Date: 01/Feb/2011

Abstract:

Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.

Priority: EP20040005849 Applic. Date: 2004-03-11; WO2004EP08821 Applic. Date: 2004-08-06; AR2004P102853 Applic. Date: 2004-08-09; US2006-518558 Applic. Date: 2006-09-08; WO2005EP02637 Applic. Date: 2005-03-11; US20040552174P Applic. Date: 2004-03-11

Inventor: EICHNER WOLFRAM [DE]; SCHIMMEL MARTIN [DE]; HACKET FRANK [DE]; KRAUS ELMAR [DE]; ZANDER NORBERT [DE]; FRANK RONALD [DE]; CONRADT HARALD [DE]; LANGER KLAUS [DE]; ORLANDO MICHELE [NL]; SOMMERMEYER KLAUS [DE]


Application No.: US20110201559A1  Published: 18/Aug/2011

Title: New Optically Pure Compounds for Improved Therapeutic Efficiency

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), IMMUPHARMA (FRANCE)

Application No.: 12/993427   Filing Date: 22/May/2008

Abstract:

The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid

n is 0 or 1

m is an integer between 0 and 3

k is an integer of at least 3

Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro

and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing.

Priority: WO2008IB53469 Applic. Date: 2008-05-22

Inventor: BRIAND JEAN PAUL [FR]; GUICHARD GILLES [FR]; COURTY JOSE [FR]; ZIMMER ROBERT [FR]; DEVIN CHANTAL [FR]; LANG ANNIE [FR]; ZHANG HAIXIANG [FR]


Application No.: US20110206668A1  Published: 25/Aug/2011

Title: METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY

Applicant/Assignee: TRILLIUM THERAPEUTICS INC

Application No.: 13/020340   Filing Date: 03/Feb/2011

Abstract:

Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.

Priority: US2009-470707 Applic. Date: 2009-05-22; US2007-736632 Applic. Date: 2007-04-18; US2004-850562 Applic. Date: 2004-05-21; US2001-948725 Applic. Date: 2001-09-10; US2001-917278 Applic. Date: 2001-07-30; US2001-934634 Applic. Date: 2001-08-23; US2000-570367 Applic. Date: 2000-05-05; WO1998CA01038 Applic. Date: 1998-11-06; US19970064764P Applic. Date: 1997-11-07; US20000222725P Applic. Date: 2000-08-03

Inventor: GORCZYNSKI REGINALD M [CA]; CLARK DAVID A [CA]


Application No.: US20110206745A1  Published: 25/Aug/2011

Title: OCTREOTIDE IMPLANT HAVING A RELEASE AGENT

Applicant/Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC

Application No.: 13/098138   Filing Date: 29/Apr/2011

Abstract:

Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.

Priority: US2009-490979 Applic. Date: 2009-06-24; US20080075625P Applic. Date: 2008-06-25; US20080080144P Applic. Date: 2008-07-11

Inventor: KUZMA PETR [US]; DECKER STEFANIE [US]; QUANDT HARRY [US]


Application No.: US20110207663A1  Published: 25/Aug/2011

Title: FIBROBLAST GROWTH FACTOR (FGF) ANALOGS AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF ROCHESTER

Application No.: 12/999540   Filing Date: 16/Jun/2009

Abstract:

The invention relates to novel peptide comprising FGF-P and methods of use thereof.

Priority: US20080061851P Applic. Date: 2008-06-16; WO2009US47498 Applic. Date: 2009-06-16

Inventor: OKUNIEFF PAUL [US]; ZHANG LURONG [US]


Application No.: US20110212157A1  Published: 01/Sep/2011

Title: DERMAL DELIVERY

Applicant/Assignee: ANTERIOS, INC

Application No.: 13/000509   Filing Date: 26/Jun/2009

Abstract:

The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.

Priority: US20080076065P Applic. Date: 2008-06-26; WO2009US48972 Applic. Date: 2009-06-26

Inventor: EDELSON JONATHAN [US]; KOTYLA TIMOTHY [US]; ZHANG BOKE [US]


Application No.: US20110212161A1  Published: 01/Sep/2011

Title: TREATMENT SKIN DISORDERS

Applicant/Assignee: ASAN LABORATORIES COMPANY (CAYMAN), LIMITED

Application No.: 13/021063   Filing Date: 04/Feb/2011

Abstract:

Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.

Priority: US2010-700843 Applic. Date: 2010-02-05; US2007-848272 Applic. Date: 2007-08-31; US2006-499936 Applic. Date: 2006-08-07; US2004-798119 Applic. Date: 2004-03-11; US2002-205738 Applic. Date: 2002-07-25; US2004-843025 Applic. Date: 2004-05-10; US2005-079370 Applic. Date: 2005-03-14; US2002-132999 Applic. Date: 2002-04-26; US20100301655P Applic. Date: 2010-02-05

Inventor: CHUNG YIH-LIN [TW]; PUI NAM-MEW [TW]; CHANG WEI-WEI [US]


Application No.: US20110212162A1  Published: 01/Sep/2011

Title: LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS

Applicant/Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 13/024445   Filing Date: 10/Feb/2011

Abstract:

Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.

Priority: US2007-670318 Applic. Date: 2007-02-01; US20060764175P Applic. Date: 2006-02-01

Inventor: RUOSLAHTI ERKKI [US]; ZHANG LIANGLIN [US]; HANAHAN DOUGLAS [US]


Application No.: US20110212883A1  Published: 01/Sep/2011

Title: RADICAL SCAVENGER AND ACTIVE OXYGEN ELIMINATING AGENT

Applicant/Assignee: INBIOTEX INC

Application No.: 12/986376   Filing Date: 07/Jan/2011

Abstract:

It is an object to provide a radical scavenger, an active oxygen-scavenging agent and the like, which are highly efficacious clinically and novel, and so as to attain the object, 3,4-dihydroxyphenylalanine derivatives such as N-[beta]-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) or pharmaceutically acceptable salts thereof are contained as an active ingredient.

Priority: JP20050166842 Applic. Date: 2005-06-07; US2007-916942 Applic. Date: 2007-12-07; WO2006JP311269 Applic. Date: 2006-06-06

Inventor: NATORI SHUNJI [JP]; OOTSU KUNIMIKI [JP]; OKUYAMA HAJIME [JP]


Application No.: US20110212890A1  Published: 01/Sep/2011

Title: METASTIN DERIVATIVE AND USE THEREOF

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 13/056297   Filing Date: 29/Jul/2009

Abstract:

Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis inhibiting activity, a cancer proliferation inhibiting activity, a gonadotropin secretion promoting activity, a sex hormone secretion promoting activity). A metastin derivative produced by substituting a constituent amino acid in metastin can be improved in stability in the blood and can have an excellent cancer metastasis inhibiting activity, an excellent cancer proliferation inhibiting activity, an excellent gonadotropin secretion inhibiting activity, an excellent sex hormone secretion inhibiting activity and the like by binding the metastin derivative to polyethylene glycol.

Priority: JP20080196598 Applic. Date: 2008-07-30; WO2009JP63533 Applic. Date: 2009-07-29

Inventor: ASAMI TAIJI [JP]


Application No.: US20110217249A1  Published: 08/Sep/2011

Title: Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds

Applicant/Assignee:

Application No.: 13/038524   Filing Date: 02/Mar/2011

Abstract:

The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.

Priority: US20100310168P Applic. Date: 2010-03-03

Inventor: DREHER FRANK [US]


Application No.: US20110217277A1  Published: 08/Sep/2011

Title: DRUG OR DERMATOLOGICAL COMPOSITION CONTAINING AN AVOCADO PEPTIDE EXTRACT FOR TREATING AND PREVENTING PRURITUS

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: 13/128109   Filing Date: 06/Nov/2009

Abstract:

The invention relates to a drug or a dermatological composition containing an avocado peptide extract for treating and/or preventing pruritus, in particular gravidic pruritus, pruritus sine materia, pruritus in newborns, and pruritus originating from a drug.

Priority: FR20080057583 Applic. Date: 2008-11-07; WO2009EP64785 Applic. Date: 2009-11-06

Inventor: MSIKA PHILIPPE [FR]; BAUDOIN CAROLINE [FR]; BREDIF STEPHANIE [FR]


Application No.: US20110217346A1  Published: 08/Sep/2011

Title: EMULSION CONTAINING ORGANOSILICON-BASED PORTIONS OF HOLLOW SPHERES

Applicant/Assignee: L'OREAL

Application No.: 13/110486   Filing Date: 18/May/2011

Abstract:

The present invention relates to a composition in the form of an emulsion containing portions of hollow spheres of organosilicon-based material, the portions of hollow spheres having a mean diameter ranging from 0.05 to 10 [mu]m. The invention also relates to physiologically acceptable emulsion compositions comprising hollow spheres, and to a process for fading out skin surface defects, in particular to reduce the sheen of the skin and/or to fade out pores, shadows under the eyes, marks, wrinkles and/or fine lines, comprising the topical application to the skin of the above-mentioned compositions.

Priority: FR20030050829 Applic. Date: 2003-11-13; US2004-982925 Applic. Date: 2004-11-08; US20030529754P Applic. Date: 2003-12-17

Inventor: CASSIN GUILLAUME [FR]


Application No.: US20110218143A1  Published: 08/Sep/2011

Title: COMPOSITIONS AND METHODS FOR TISSUE REPAIR

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION

Application No.: 12/743907   Filing Date: 20/Nov/2008

Abstract:

The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof.

Priority: US20070003785P Applic. Date: 2007-11-20; US20070003787P Applic. Date: 2007-11-20; US20070003786P Applic. Date: 2007-11-20; US20070003824P Applic. Date: 2007-11-20; US20080083070P Applic. Date: 2008-07-23; WO2008US13000 Applic. Date: 2008-11-20

Inventor: KAUSHAL SHALESH [US]; ANNAMALAI MANI [US]


Application No.: US20110230397A1  Published: 22/Sep/2011

Title: PEPTIDES HAVING PHARMACOLOGICAL ACTIVITY FOR TREATING DISORDERS ASSOCIATED WITH ALTERED CELL MIGRATION, SUCH AS CANCER

Applicant/Assignee:

Application No.: 12/376465   Filing Date: 19/Jul/2007

Abstract:

Peptides and their functionally equivalent derivatives, in salified or non-salified form, with the general formula L1-X1-X2-X3-X4, wherein: L1 is H, or acyl, or any natural or non-natural amino acid, optionally N-acylated, N-alkylated and/or C[alpha]-alkylated

X1 and X3, which are equal or different, are any natural or non-natural basic amino acid, optionally N-alkylated and/or C[alpha]-alkylated

X2 is any natural or non-natural amino acid, optionally N-alkylated and/or C[alpha]-alkylated, with the proviso that it is not glycine and amino acids mono-substituted on the [alpha] carbon atom with a linear or cyclic alkyl group, from 1 to 10 carbon atoms, and amino acids mono-substituted on the [alpha] carbon atom with a linear or cyclic alkyl group containing 4 to 10 carbon atoms, or amino acids mono-substituted on the [alpha] carbon atom with an alkyl group containing 1 to 8 carbon atoms, optionally substituted with a carbamoyl, hydroxyl or aromatic group

X4 is any natural or non-natural hydrophobic amino acid, optionally C[alpha]-alkylated and/or amidated at the C-terminal end, or any hydrophobic amino alcohol, or a hydrophobic gem-diamine, optionally N'-alkylated or N'-acylated.

Priority: IT2006MI01607 Applic. Date: 2006-08-09; WO2007EP06424 Applic. Date: 2007-07-19

Inventor: CARRIERO MARIA VINCENZA [IT]; DE ROSA MARIO [IT]; PAVONE VINCENZO [IT]


Application No.: US20110230415A1  Published: 22/Sep/2011

Title: Pharmaceutical Composition Containing GHRP-6 To Prevent And Eliminate Fibrosis And Other Pathological Deposits In Tissues

Applicant/Assignee:

Application No.: 13/150526   Filing Date: 01/Jun/2011

Abstract:

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Priority: CU20060000048 Applic. Date: 2006-02-28; US2009-281018 Applic. Date: 2009-01-14; WO2007CU00005 Applic. Date: 2007-02-23

Inventor: BERLANGA ACOSTA JORGE [CU]; VERA DANAY CIBRIAN [CU]; DEL BARCO HERRERA DIANA GARCIA [CU]; GUILLEN NIETO GERARDO ENRIQUE [CU]; ALBA JOSE SUAREZ [CU]; MOLA ERNESTO LOPEZ [CU]; SOSA MANUEL SELMAN-HOUSEIN [CU]; CASTILLO MARIELA VAZQUEZ [CU]


Application No.: US20110230417A1  Published: 22/Sep/2011

Title: TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY INCREASED PHOSPHORYLATION

Applicant/Assignee:

Application No.: 13/152072   Filing Date: 02/Jun/2011

Abstract:

The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC.

Priority: US2003-723247 Applic. Date: 2003-11-25; US20020429924P Applic. Date: 2002-11-27

Inventor: BAR-OR DAVID [US]


Application No.: US20110236325A1  Published: 29/Sep/2011

Title: METHODS TO TREAT OR PREVENT A SKIN CONDITION USING A NELL1 PEPTIDE

Applicant/Assignee: NELLONE THERAPEUTICS, INC

Application No.: 13/011339   Filing Date: 21/Jan/2011

Abstract:

The described invention provides methods and compositions utilizing a NELL1 peptide or nucleic acid encoding a NELL1 peptide for treating or preventing a skin condition. The methods include treating or preventing manifestations of aging in human skin, repairing damage to skin, and preventing skin scarring. Methods are also provided for assaying a test peptide for NELL1 activity.

Priority: US20100296965P Applic. Date: 2010-01-21

Inventor: MITCHELL DORA P [US]; CULIAT CYMBELINE T [US]; LUBIT BEVERLY W [US]


Application No.: US20110236367A1  Published: 29/Sep/2011

Title: RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES

Applicant/Assignee: TELENAV, INC

Application No.: 12/784139   Filing Date: 20/May/2010

Abstract:

The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme.

Priority: DK20000001343 Applic. Date: 2000-09-08; US2003-363712 Applic. Date: 2003-08-15; WO2001DK00580 Applic. Date: 2001-09-06; US20000247584P Applic. Date: 2000-11-09

Inventor: OLSEN JOHAN GOTTHARDT [DK]; KADZIOLA ANDERS [DK]; DAHL SOEREN WEIS [DK]; LAURITZEN CONNIE [DK]; LARSEN SINE [DK]; PEDERSEN JOHN [DK]; TURK DUSAN [SI]; PODOBNIK MARJETKA [SI]; STERN IGOR [SI]


Application No.: US20110237497A1  Published: 29/Sep/2011

Title: COMPOSITIONS OF A V-ATPASE INHIBITOR IN COMBINATION WITH A GLUCOCORTICOID RECEPTOR LIGAND AND METHODS OF USE

Applicant/Assignee:

Application No.: 12/949432   Filing Date: 18/Nov/2010

Abstract:

A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having an inflammatory or auto-immune disease by administering such composition.

Priority: US20090262377P Applic. Date: 2009-11-18

Inventor: XU HUAQIANG ERIC [US]; XU YONG [US]; HE YUANZHENG [US]


Application No.: US20110237516A1  Published: 29/Sep/2011

Title: PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME

Applicant/Assignee:

Application No.: 12/781710   Filing Date: 17/May/2010

Abstract:

The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.

Priority: US2006-405843 Applic. Date: 2006-04-17; US20050671557P Applic. Date: 2005-04-15; US20050737586P Applic. Date: 2005-11-17

Inventor: JIMENEZ FELIPE [US]; MITTS THOMAS F [US]; HINEK ALEKSANDER [CA]


Application No.: US20110239311A1  Published: 29/Sep/2011

Title: Agonists of NR2F6 For Immunosupression

Applicant/Assignee: MEDIZINISCHE UNIVERSITAT INNSBRUCK

Application No.: 13/004831   Filing Date: 11/Jan/2011

Abstract:

The present invention relates to agonists/activators of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an augmented immune response. Furthermore, pharmaceutical compositions comprising said agonists/activators of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunosuppressants comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-activation with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunosuppressants. In yet another aspect, the present invention relates to ligand-mediated reporter gene expression constructs, ligand displacement constructs, fluorescent cellular sensor fusion mutant constructs, and ligand-induced homo- and/or heterodimer constructs useful in the provided methods for identifying immunosuppressants.

Priority: EP20080012630 Applic. Date: 2008-07-11; WO2009EP58882 Applic. Date: 2009-07-10

Inventor: BAIER GOTTFRIED [AT]; HERMANN-KLEITER NATASCHA [AT]


Application No.: US20110245181A1  Published: 06/Oct/2011

Title: Compositions and Methods for Skin Treatment

Applicant/Assignee:

Application No.: 12/895940   Filing Date: 01/Oct/2010

Abstract:

Compositions for the treatment of the skin. The compositions reduce and/or reverse the visible appearance of skin damage. In the preferred embodiment, the composition includes Retinyl Palmitate Polypeptide

Ascorbylmethylsilanol Pectinate

Tocopheryl Polypeptide

Cholecalciferol Polypeptide

and Niacinamide Polypeptide.

Priority: US1998-022233 Applic. Date: 1998-02-11

Inventor: ERANI SIMON [US]


Application No.: US20110250147A1  Published: 13/Oct/2011

Title: Method and System for Reducing Skin Friction

Applicant/Assignee: BRANDS WORLDWIDE HOLDINGS I.P. PTY LIMITED

Application No.: 12/787399   Filing Date: 26/May/2010

Abstract:

A film forming material can be used for the preparation of a medicament for pre-treating an area of skin to reduce causes of skin irritation, resulting in a educed risk of acquiring skin chafing and/or blisters. A method of pre-treating can comprise the steps of: providing a dispensing device containing a film forming material

and applying a film forming material to an area of skin, for pre-treating an area of skin to reduce friction and thereby reduce the risk of acquiring chafing and/or a blister.

Priority: AU20100201452 Applic. Date: 2010-04-13

Inventor: SHER STEVEN [AU]; SAHA AMIT [AU]


Application No.: US20110250151A1  Published: 13/Oct/2011

Title: COLD PROCESS WATER SOLUBLE WAX CONTAINING POWDERS

Applicant/Assignee: JEEN INTERNATIONAL

Application No.: 12/832547   Filing Date: 08/Jul/2010

Abstract:

Inventive subject matter described herein includes a powder comprising: a wax having a melt point within a range of 45 to 100 degrees Centigrade and sodium polyacrylate or salts of sodium polyacrylate or sodium polyacrylate and salts of sodium polyacrylate wherein the wax concentration falls within a range of 99.9% to 0.1% by weight and the sodium polyacrylate concentration falls within a range of 0.1% to 99.9% by weight, wherein the powder is effective for forming a cream or lotion or gel or coating when mixed with water at room temperature or cooler than room temperature.

Priority: US20100347664P Applic. Date: 2010-05-24; US20100321765P Applic. Date: 2010-04-07

Inventor: MATEU JUAN R [US]; PERLE ADAM [US]


Application No.: US20110256130A1  Published: 20/Oct/2011

Title: METHODS OF TREATING INFLAMMATORY DISORDERS

Applicant/Assignee:

Application No.: 13/125035   Filing Date: 01/Dec/2009

Abstract:

Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of modulators of inflammation.

Priority: US20080118938P Applic. Date: 2008-12-01; US20080121779P Applic. Date: 2008-12-11; WO2009US66180 Applic. Date: 2009-12-01

Inventor: SCHULTZ JOSHUA ROBERT [US]; VOLLRATH BENEDIKT [US]; TURNER COURT [US]


Application No.: US20110258713A1  Published: 20/Oct/2011

Title: COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION

Applicant/Assignee: VIVOSCRIPT, INC

Application No.: 13/141326   Filing Date: 23/Dec/2009

Abstract:

The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.

Priority: US20080203438P Applic. Date: 2008-12-23; US20090210586P Applic. Date: 2009-03-19; US20090216511P Applic. Date: 2009-05-18; US20090226659P Applic. Date: 2009-07-17; WO2009US69518 Applic. Date: 2009-12-23

Inventor: ZHU YONG [US]; WU SHILI [US]; BAO JUN [US]


Application No.: US20110262432A1  Published: 27/Oct/2011

Title: MUTATED NETRIN 4 PROTEINS, FRAGMENTS THEREOF AND THEIR USES AS DRUGS

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Application No.: 13/054731   Filing Date: 16/Jul/2009

Abstract:

A mutated protein includes the sequence of wild type netrin 4, represented by SEQ ID NO: 2, wherein at least one amino acid of the amino acids at position (13, 68, 183, 205, 234, 331, 332, 353, 472, 515, 589, 625, 626, 627) and (628) is mutated enabling thus to confer 1 to 15 mutations to the wild type protein, or, truncated protein derived from the mutated protein, wherein the 19 first contiguous, or the 31 first contiguous amino acids at the N-terminus part of the mutated protein are deleted

and/or the mutated protein being deleted of all amino acids located after the amino acid in position (477) or of all amino acids located after the amino acid in position (515).

Priority: EP20080290707 Applic. Date: 2008-07-18; WO2009EP59189 Applic. Date: 2009-07-16

Inventor: PLOUET JEAN [FR]; PLOUET ISABELLE CLARISSE SOLANGE [FR]; PLOUET CLAIRE CHARLOTTE [FR]; PLOUET ANNE FLORENCE [FR]; LECONTE LAURENCE [FR]; LEJMI ESMA [FR]


Application No.: US20110263486A1  Published: 27/Oct/2011

Title: Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation

Applicant/Assignee: 4SC AG

Application No.: 13/046072   Filing Date: 11/Mar/2011

Abstract:

The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is -NRaRb, -NRc-ONRaRb, -NRcC-SNRaRb, -NRcC-NRdNaRb, heterocycle, -C-ONRaRb, heterocycle, or aryl

n is 0 to 8

m is 0, or 1

r is 0 to 3

t is 0 to 3

X is O or N

Z is CH2, C-O, C-S or a single bond

Z1 is CO-R2, CS-R2, (CH2)t-R2 or the side-chain of a naturally occurring amino acid

Z2 is CO-R2, CS-R2 or (CH2)t-R3 or the side-chain of a naturally occurring amino acid

Z3 is CO-R2, CS-R2 or (CH2)t-R4 or the side-chain of a naturally occurring amino acid

Z4 is H, alkyl, alkoxy, or cycloalkyl

R1, R2, R3, and R4 are independently from each other H, OH, SH, NH2, CN, NO2, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylamino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.

Priority: US2009-400680 Applic. Date: 2009-03-09; US2006-501722 Applic. Date: 2006-08-10

Inventor: LEBAN JOHANN [DE]; KRALIK MARTIN [DE]


Application No.: US20110263504A1  Published: 27/Oct/2011

Title: TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE

Applicant/Assignee:

Application No.: 12/863973   Filing Date: 22/Jan/2009

Abstract:

The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.

Priority: US20080062012P Applic. Date: 2008-01-22; US20080062022P Applic. Date: 2008-01-22; US20080062045P Applic. Date: 2008-01-22; US20080133912P Applic. Date: 2008-07-03; US20080203890P Applic. Date: 2008-12-30; WO2009US00424 Applic. Date: 2009-01-22

Inventor: CERAMI ANTHONY [US]; BRINES MICHAEL [US]


Application No.: US20110263508A1  Published: 27/Oct/2011

Title: Compositions and methods for including melanogenesis in a subject

Applicant/Assignee: CLINUVEL PHARMACEUTICALS LIMITED

Application No.: 11/664879   Filing Date: 07/Oct/2005

Abstract:

Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.

Priority: US20040617359P Applic. Date: 2004-10-08; WO2005AU01552 Applic. Date: 2005-10-07

Inventor: KLEINIG MICHAEL JOHN [AU]; KIRBY KENNETH B [US]; PETTERSSON JR BERNO I [US]


Application No.: US20110268679A1  Published: 03/Nov/2011

Title: COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS

Applicant/Assignee:

Application No.: 13/180149   Filing Date: 11/Jul/2011

Abstract:

Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.

Priority: US2006-412618 Applic. Date: 2006-04-27; US20050675707P Applic. Date: 2005-04-28

Inventor: SHERRIS DAVID [US]


Application No.: US20110269691A1  Published: 03/Nov/2011

Title: Compositions and Methods for Treating Pigmentary Conditions and Melanoma

Applicant/Assignee:

Application No.: 13/059219   Filing Date: 15/Aug/2008

Abstract:

A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer. A method of sensitizing a melanoma cell to RA comprising administering to the subject an amount of SOX9 sufficient to decrease PRAME expression. A method of increasing p21 expression in a subject comprising administering to the subject an amount of SOX9 sufficient to increase p21 expression. Methods of screening for compounds that treat hypopigmentary conditions and/or melanoma are provided.

Priority: WO2008US09762 Applic. Date: 2008-08-15

Inventor: HEARING VINCENT J [US]; PASSERON THIERRY [FR]


Application No.: US20110269692A1  Published: 03/Nov/2011

Title: ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF

Applicant/Assignee:

Application No.: 13/108923   Filing Date: 16/May/2011

Abstract:

Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5

a peptidomimetic

or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy.

Priority: US2006-582629 Applic. Date: 2006-10-17; US2002-300530 Applic. Date: 2002-11-20; US20010331841P Applic. Date: 2001-11-20; US20010340926P Applic. Date: 2001-12-07; US20020397373P Applic. Date: 2002-07-19; US20020397012P Applic. Date: 2002-07-19; US20020409109P Applic. Date: 2002-09-09

Inventor: ANDERSEN THOMAS T [US]; BENNETT JAMES A [US]; JACOBSON HERBERT I [US]; MESFIN FASSIL B [US]


Application No.: US20110269694A1  Published: 03/Nov/2011

Title: NOVEL ANTI-AGING PEPTIDES AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: ISP INVESTMENTS

Application No.: 13/143741   Filing Date: 07/Jan/2010

Abstract:

The present invention relates to peptide compounds of general formula (I) R1-X1-X2-Ser-Pro-Leu-Gln-X3-X4-R2. The present invention also relates, on the one hand, to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I) in a cosmetically or dermatologically acceptable medium, and on the other hand to its use in order to prevent or treat the cutaneous signs of aging and to protect the skin against the harmful effects caused by UV radiation. The invention lastly relates to a cosmetic treatment method for preventing and/or combating cutaneous signs of aging and for protecting the skin against the harmful effects caused by UV radiation.

Priority: FR20090000069 Applic. Date: 2009-01-09; WO2010FR00007 Applic. Date: 2010-01-07

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]; IMBERT ISABELLE [FR]


Application No.: US20110269695A1  Published: 03/Nov/2011

Title: NOVEL ANTI-AGING PEPTIDES AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: ISP INVESTMENTS

Application No.: 13/143754   Filing Date: 07/Jan/2010

Abstract:

Peptide compounds of general formula (I) R1-(AA)n-X1-Ser-Thr-Pro-X2-(AA)p-R2 were developed that restore the circadian rhythm and resynchronize the biological clock of skin cells. Cosmetic or pharmaceutical compositions that include at least one peptide of general formula (I) in a cosmetically or dermatologically acceptable medium, and a cosmetic treatment method for restoring the circadian rhythm and resynchronising the biological clock of cells to reduce the dysfunctions caused by jet lag and/or nightshift work and/or to prevent or treat the cutaneous signs of aging were also developed.

Priority: FR20090000066 Applic. Date: 2009-01-09; WO2010FR00006 Applic. Date: 2010-01-07

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]; IMBERT ISABELLE [FR]


Application No.: US20110275562A1  Published: 10/Nov/2011

Title: INHIBITION OF GLIADIN PEPTIDES

Applicant/Assignee:

Application No.: 12/991658   Filing Date: 06/May/2009

Abstract:

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

Priority: US20080050915P Applic. Date: 2008-05-06; WO2009US42973 Applic. Date: 2009-05-06

Inventor: ALKAN SEFIK [US]; TAMIZ AMIR [US]; KITCHENS KELLY MARIE [US]; DURAI MALARVIZHI [US]; POLOSO NEIL [US]; CARRASCO ROSA A [US]


Application No.: US20110280876A1  Published: 17/Nov/2011

Title: MUTATED NETRIN - 4, FRAGMENTS THEREOF AND THEIR USE AS MEDICINES

Applicant/Assignee: IVS INSTITUT DES VAISSEAUX ET DU SANG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Application No.: 13/171756   Filing Date: 29/Jun/2011

Abstract:

A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies.

Priority: FR20040012362 Applic. Date: 2004-11-22; FR20040012364 Applic. Date: 2004-11-22; US2007-791274 Applic. Date: 2007-07-13; WO2005FR02898 Applic. Date: 2005-11-22

Inventor: PLOUET JEAN [FR]; ALEMANY MONICA [FR]


Application No.: US20110280882A1  Published: 17/Nov/2011

Title: LEUKOLECTINS AND USES THEREOF

Applicant/Assignee: LEUKOLECT AS

Application No.: 13/126225   Filing Date: 29/Oct/2009

Abstract:

The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.

Priority: GB20080019883 Applic. Date: 2008-10-29; WO2009GB02569 Applic. Date: 2009-10-29

Inventor: WALTHER BERNT TH [NO]; MIFTARI MIRUSHE [NO]


Application No.: US20110287040A1  Published: 24/Nov/2011

Title: MATERIALS AND METHODS FOR TREATMENT OF INFLAMMATION

Applicant/Assignee:

Application No.: 13/113392   Filing Date: 23/May/2011

Abstract:

The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.

Priority: US20100347102P Applic. Date: 2010-05-21

Inventor: MAIONE THEODORE E [US]; CAROZZA JOSEPH [US]; MAGLARIS C DEAN [US]


Application No.: US20110288025A1  Published: 24/Nov/2011

Title: BIOPOLYMER PRODUCED BY FERMENTING THE EXTRACT OF SOYBEAN WITH FOLIC ACID AND A COMPOSITION CONTAINING THEREOF

Applicant/Assignee: DAMY CHEMICAL CO., LTD

Application No.: 12/681725   Filing Date: 02/Oct/2008

Abstract:

Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.

Priority: KR20070100311 Applic. Date: 2007-10-05; WO2008KR05816 Applic. Date: 2008-10-02

Inventor: CHO BOO SUN [KR]; KIM KWANG NYEON [KR]


Application No.: US20110288031A1  Published: 24/Nov/2011

Title: IDENTIFICATION OF A NOVEL BHD GENE

Applicant/Assignee: THE GOV'T OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEP'T OF HEALTH AND HUMAN SERVICE

Application No.: 13/179853   Filing Date: 11/Jul/2011

Abstract:

The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions.

Priority: US2008-334361 Applic. Date: 2008-12-12; US2004-514744 Applic. Date: 2004-11-16; WO2003US17227 Applic. Date: 2003-05-30; US20020385181P Applic. Date: 2002-05-31; US20020390291P Applic. Date: 2002-06-20

Inventor: SCHMIDT LAURA S [US]; WARREN MICHELLE [US]; TORO JORGE R [US]; ZBAR BERTON [US]; NICKERSON MICHAEL L [US]; LINEHAN W MARSTON [US]; TURNER MARIA L [US]


Application No.: US20110293557A1  Published: 01/Dec/2011

Title: CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS

Applicant/Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L

Application No.: 12/997829   Filing Date: 12/Jun/2009

Abstract:

The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule.

Priority: ES20080001796 Applic. Date: 2008-06-13; WO2009ES70224 Applic. Date: 2009-06-12

Inventor: PRIETO VALTUENA JESUS MARIA [ES]; BERRAONDO LOPEZ PEDRO [ES]; FIORAVANTI JESSICA [ES]


Application No.: US20110293610A1  Published: 01/Dec/2011

Title: ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN

Applicant/Assignee: HUMAN GENOME SCIENCES, INC

Application No.: 13/209197   Filing Date: 12/Aug/2011

Abstract:

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Priority: US2009-605202 Applic. Date: 2009-10-23; US2005-054515 Applic. Date: 2005-02-10; US2002-293418 Applic. Date: 2002-11-14; US2001-880748 Applic. Date: 2001-06-15; US20040543296P Applic. Date: 2004-02-11; US20040580347P Applic. Date: 2004-06-18; US20010331469P Applic. Date: 2001-11-16; US20010340817P Applic. Date: 2001-12-19; US20000212210P Applic. Date: 2000-06-16; US20000240816P Applic. Date: 2000-10-17; US20010276248P Applic. Date: 2001-03-16; US20010277379P Applic. Date: 2001-03-21; US20010293499P Applic. Date: 2001-05-25

Inventor: RUBEN STEVEN M [US]; BARASH STEVEN C [US]; CHOI GIL H [US]; VAUGHAN TRISTAN [GB]; HILBERT DAVID [US]


Application No.: US20110294731A1  Published: 01/Dec/2011

Title: SKIN CREAM

Applicant/Assignee: INVITRX, INC

Application No.: 13/201244   Filing Date: 12/Feb/2010

Abstract:

Preferred embodiments of the invention relate to compositions, including anti-aging cosmeceuticals for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture.

Priority: US20090152644P Applic. Date: 2009-02-13; WO2010US23987 Applic. Date: 2010-02-12

Inventor: TORFI HABIB [US]


Application No.: US20110294738A1  Published: 01/Dec/2011

Title: PTHR1 RECEPTOR COMPOUNDS

Applicant/Assignee:

Application No.: 13/127694   Filing Date: 04/Nov/2009

Abstract:

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis

humoral hypercalcemia of malignancy

osteolytic and osteoblastic metastasis to bone

primary and secondary hyperparathyroidism associated increase in bone absorption

vascular calcification

psychiatric disorders and cognitive disorders associated with hyperparathyroidism

dermatological disorders

and excess hair growth.

Priority: US20080198299P Applic. Date: 2008-11-04; WO2009US05977 Applic. Date: 2009-11-04

Inventor: REN YONG [US]; KULIOPULOS ATHAN [US]; MCMURRY THOMAS J [US]


Application No.: US20110300199A1  Published: 08/Dec/2011

Title: PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR SCALP AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: LIPOTEC, S.A

Application No.: 13/201374   Filing Date: 16/Feb/2010

Abstract:

Peptides of general formula (I): R1-Wp-Xn-AA1-AA2-AA3-AA4-Ym-R2 their stereoisomers, mixtures thereof, and/or their cosmetically or pharmaceutically acceptable salts, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment, prevention and/or care of conditions, disorders and/or diseases of the skin, mucous membranes and/or scalp.

Priority: ES20090000426 Applic. Date: 2009-02-16; WO2010EP00937 Applic. Date: 2010-02-16

Inventor: GARCIA SANZ NURIA [ES]; VAN DEN NEST WIM [ES]; CARRENO SERRAIMA CRISTINA [ES]; FERRER MONTIEL ANTONIO [ES]; CEBRIAN PUCHE JUAN [ES]; ALMINANA DOMENECH NURIA [ES]


Application No.: US20110301090A1  Published: 08/Dec/2011

Title: SKIN WOUND HEALING COMPOSITIONS AND METHODS OF USE THEREOF

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: 13/210200   Filing Date: 15/Aug/2011

Abstract:

A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90[alpha] or the middle domain plus the charged sequence of hsp90[alpha]. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound.

Priority: US2009-522446 Applic. Date: 2009-07-08; WO2008US50520 Applic. Date: 2008-01-08; US20070879150P Applic. Date: 2007-01-08

Inventor: LI WEI [US]; CHEN MEI [US]; WOODLEY DAVID T [US]


Application No.: US20110301091A1  Published: 08/Dec/2011

Title: COMPOSITIONS AND METHODS FOR REDUCING THE SIGNS OF AGING OF THE SKIN

Applicant/Assignee:

Application No.: 13/127249   Filing Date: 03/Nov/2009

Abstract:

Compositions and methods used to reduce the visible signs of aging of the skin by recalibrating the expression of genes, genetic networks, and cellular pathways in the human skin, particularly using combinations of natural compounds that produce synergistic effects on the expression of genes and genetic networks.

Priority: US20080198235P Applic. Date: 2008-11-03; WO2009US63137 Applic. Date: 2009-11-03

Inventor: GIULIANI GIAMMARIA [IT]; RODRIGUEZ RAYMOND [US]; DAWSON KEVIN [US]


Application No.: US20110305634A1  Published: 15/Dec/2011

Title: Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)

Applicant/Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Application No.: 13/158246   Filing Date: 10/Jun/2011

Abstract:

The present invention provides compositions and methods for treating disorders associated with epithelial tissues.

Priority: US20100353652P Applic. Date: 2010-06-10; US201161430091P Applic. Date: 2011-01-05; US201161470663P Applic. Date: 2011-04-01

Inventor: LIEBER ANDRE [US]; WANG HONGJIE [US]


Application No.: US20110306560A1  Published: 15/Dec/2011

Title: BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 13/213157   Filing Date: 19/Aug/2011

Abstract:

Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Priority: US2009-416193 Applic. Date: 2009-04-01; US2008-006422 Applic. Date: 2008-01-02; US2006-642372 Applic. Date: 2006-12-20; US2005-252291 Applic. Date: 2005-10-17; US2003-730231 Applic. Date: 2003-12-08; US2003-392165 Applic. Date: 2003-03-19; US2002-125997 Applic. Date: 2002-04-19; US2002-100295 Applic. Date: 2002-03-18; US2001-953540 Applic. Date: 2001-09-14; US2000-490511 Applic. Date: 2000-01-25; US1998-085404 Applic. Date: 1998-05-26; US1995-549318 Applic. Date: 1995-10-27; US1995-442581 Applic. Date: 1995-05-16; US1994-330525 Applic. Date: 1994-10-28

Inventor: ADAMS JULIAN [US]; MA YU-TUNG [US]; STEIN ROSS [US]; BAEVSKY MATTHEW [US]; GRENIER LOUIS [US]; PLAMONDON LOUIS [US]


Application No.: US20110311529A1  Published: 22/Dec/2011

Title: METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE TLA4 MOLECULE

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 13/191923   Filing Date: 27/Jul/2011

Abstract:

The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Priority: US2003-419008 Applic. Date: 2003-04-18; US2001-898195 Applic. Date: 2001-07-02; US20000215913P Applic. Date: 2000-07-03; US20020373852P Applic. Date: 2002-04-19; US20020407246P Applic. Date: 2002-08-30

Inventor: COHEN ROBERT [US]; CARR SUZETTE [US]; HAGERTY DAVID [US]; PEACH ROBERT JAMES [US]; BECKER JEAN-CLAUDE [US]


Application No.: US20110311564A1  Published: 22/Dec/2011

Title: Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles

Applicant/Assignee:

Application No.: 13/000516   Filing Date: 23/Jun/2009

Abstract:

The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.

Priority: EP20080011346 Applic. Date: 2008-06-23; WO2009EP04526 Applic. Date: 2009-06-23

Inventor: KALESSE MARKUS [DE]; BUELOW LEILA [DE]; RENTSCH ANDREAS [DE]; GIRBIG ANNA-KATHARINA [DE]; EGGERT ULRIKE [DE]; MALEK NISAR [DE]; FRANK RONALD [DE]; BRODMANN TOBIAS [DE]


Application No.: US20110311613A1  Published: 22/Dec/2011

Title: TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS

Applicant/Assignee: AMIRA PHARMACEUTICAL, INC

Application No.: 13/141665   Filing Date: 21/Dec/2009

Abstract:

Described herein, are topical formulations for treating a dermatological disease, disorder, or condition. Topical formulations disclosed herein include a therapeutically-effective amount of a FLAP inhibitor formulated for dermal administration

Priority: US20080140522P Applic. Date: 2008-12-23; WO2009US69065 Applic. Date: 2009-12-21

Inventor: HUTCHINSON JOHN HOWARD [US]; EVANS JILLIAN F [US]; SCHAAB KEVIN MURRAY [US]


Application No.: US20110318433A1  Published: 29/Dec/2011

Title: SOOTHING PHARMACEUTICAL OR COSMETIC COMPOSITION COMPRISING A PEPTIDE THAT ACTIVATES HMG-COA REDUCTASE

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/141392   Filing Date: 23/Dec/2009

Abstract:

The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2 and a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.

Priority: FR20080007365 Applic. Date: 2008-12-23; WO2009FR01477 Applic. Date: 2009-12-23

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20110319317A1  Published: 29/Dec/2011

Title: TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1

Applicant/Assignee: OPKO CURNA, LLC

Application No.: 13/254600   Filing Date: 03/Mar/2010

Abstract:

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.

Priority: WO2009US66445 Applic. Date: 2009-12-02; US20090157255P Applic. Date: 2009-03-04; US20090259072P Applic. Date: 2009-11-06; WO2010US26119 Applic. Date: 2010-03-03

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]; COITO CARLOS [US]; DE LEON BELINDA [US]


Application No.: US20110319330A1  Published: 29/Dec/2011

Title: Methods For Treating Arthritis, Autoimmune Disease, and Ischemia-Reperfusion Injury

Applicant/Assignee: BIO HOLDING, INC

Application No.: 12/767858   Filing Date: 27/Apr/2010

Abstract:

The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes [alpha]1-antitrypsin or an [alpha]1-antitrypsin-like agent, including, but not limited to oxidation-resistant variants of [alpha]1-antitrypsin, and peptoids with antitrypsin activity. The diseases treatable by the invention include cancer, autoimmune disease, sepsis neurodegenerative disease, myocardial infarction, stroke, ischemia-reperfusion injury, toxin induced liver injury and AIDS. The method of the invention is also suitable for the prevention or amelioration of diseases characterized by excessive apoptosis.

Priority: US2000-518081 Applic. Date: 2000-03-03; US19990123167P Applic. Date: 1999-03-05

Inventor: SHAPIRO LELAND [US]

Clck to enlarge and view details
US Patent Applications  in 2012
 
US Patent Applications  in 2010
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..